



(51) International Patent Classification:

C07D 471/04 (2006.01) C07D 409/12 (2006.01)  
C07D 401/12 (2006.01) C07D 413/12 (2006.01)  
C07D 401/10 (2006.01) A61K 31/519 (2006.01)  
C07D 407/10 (2006.01) A61P 31/04 (2006.01)

(21) International Application Number:

PCT/EP2019/054476

(22) International Filing Date:

22 February 2019 (22.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18158343.6 23 February 2018 (23.02.2018) EP

(71) Applicant: **FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.** [DE/DE]; Hansastraße 27 c, 80686 München (DE).

(72) Inventors: **JÄGER, Christian**; Wittekindstraße 13b, 06114 Halle (Saale) (DE). **LIEBE, Linda**; Zinksgarten-

straße 12, 06108 Halle (Saale) (DE). **RAMSBECK, Daniel**; Jasminweg 6, 06118 Halle (Saale) (DE). **LIN-NERT, Miriam**; Brennesselweg 4, 06118 Halle (Saale) (DE). **GEISSLER, Stefanie**; Robert-Koch-Str. 40, 06110 Halle (Saale) (DE). **PIECHOTTA, Anke**; Bernhardysstraße 20, 06110 Halle (Saale) (DE). **MEITZNER, Diane**; Lessingstraße 1, 06766 Wolfen (DE). **HOLGER, Cynis**; Friedrich-Chrysanther-Weg 3, 06120 Halle (Saale) (DE). **BUCHHOLZ, Mirko**; Schleiermacherstr. 29, 06114 Halle (Saale) (DE).

(74) Agent: **HOFFMANN EITLÉ PATENT- UND RECHTSANWÄLTE PARTMBB**; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES




FIG. 4

(57) Abstract: The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminy cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions for use in methods for treatment, in particular for use in the treatment of periodontitis and related conditions; as well as to crystals comprising bacterial glutaminy cyclases, methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors.



OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

## NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES

### FIELD OF THE INVENTION

The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminy cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions for use in methods for treatment, in particular for use in the treatment of periodontitis and related conditions. The present disclosure also relates to crystals comprising bacterial glutaminy cyclases and methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors.

### BACKGROUND ART

Periodontal diseases are highly prevalent with about 30% of the human population being affected worldwide, have considerable impact on individuals and society, and are costly to treat. The cost of dental care is the fourth highest of all diseases and consuming between 5 and 10% of all healthcare resources (Batchelor, P. *British Dental Journal* **2014**, 217, 405–409). Representative population studies show that periodontal diseases are widespread and their prevalence has been increasing since 1997 (Micheelis, W. et al. *Vierte Deutsche Mundgesundheitsstudie (DMS IV)*, Deutscher Ärzte-Verlag, Köln, **2006**). Amongst the adult population in Germany, 52.7% were found to be affected by moderately severe and 20.5% by severe forms of periodontitis. The health insurance expenditure in Germany for the direct treatment of periodontitis amounted to about EUR 1.1 billion (*Statistisches Bundesamt*, **2008**), not including the costs incurred by secondary diseases.

Periodontitis is a general term describing inflammation condition of the periodontal apparatus which is caused by multi-bacterial induction and has strong relations to various systemic diseases, such as cardiovascular diseases, rheumatoid arthritis, chronic obstructive pulmonary disease and Alzheimer's disease.

The currently established therapy of periodontitis, according to the recommendations of the German Society Of Dental, Oral And Craniomandibular Sciences, is generally performed by manual supra and subgingival debridement (removal of the bacterial plaques) along with the application of antiseptic substances (daily disinfection by mouth washes), which disintegrates the entire oral biofilm and provides an opportunity for recolonization by potential pathogens. Furthermore, adjuvant systemic broad-spectrum antibiotic therapy is applied in advanced disease forms. The latter also leads to a non-selective destruction of the biofilm and has to be administered in high doses and over a prolonged period of time in order to reach sufficient therapeutic levels at the particular site of action, i.e. the gingival pocket. Standard adjuvant therapy of periodontitis involves, for instance, systemic administration of doxycyclin (per os) 1 × 200 mg/die for 1 day and 2 x 100 mg/die for further 18 days (*Wissenschaftliche Stellungnahme: Adjuvante Antibiotika in der Parodontistherapie*, Deutsche Gesellschaft für Zahn- Mund- und Kieferheilkunde, *DZZ* **2003**). As a result, resistance development in oral pathogens is observed. Further, the microbiome in the patient's intestine is destroyed, which leads to a loss of metabolic support, immune modulation, and enables recolonization by potential pathogens. A focused and targeted therapy along with conservation of the remaining biofilm would represent a significant improvement in the treatment of periodontitis and conditions associated therewith.

The presence of periodontopathogenic bacteria varies among periodontitis patients. Nevertheless, the occurrence of certain bacterial species in the subgingival plaques has been found to be closely associated with the etiology of periodontal diseases (Socransky et al., *Journal of Clinical Periodontology*, **1998**, 25, 134–144).

Thus, there is a high demand for the development of new treatments for periodontitis and related conditions capable of selectively targeting pathogens which induce a periodontal disease, while being essentially inactive on homologous human target proteins and preferably substantially preserving the rest of the naturally occurring biofilm. Such treatment would provide significant improvement to patients and healthcare systems.

#### PROBLEMS TO BE SOLVED BY THE INVENTION

In view of the above, the present invention aims at the object of identifying and providing compounds and/or pharmaceutical compositions useful in the treatment of periodontal and related diseases. Said compounds and/or pharmaceutical compositions should be preferably capable of selectively targeting pathogens which induce a periodontal disease. More preferably, the rest of the naturally occurring biofilm should be substantially preserved; homologous human target proteins should not be substantially inhibited. Even more preferably, the compounds and/or pharmaceutical compositions should exhibit high *in vivo* activities against the targeted pathogens.

A further object is the preparation of a crystal and/or co-crystal of therapeutic target protein(s), which can be used for identifying inhibitors capable of targeting pathogens which induce a periodontal disease, e.g., by means of structure-based drug-design.

A further object is to provide a method for identifying a candidate compound which may associate with a binding pocket of said therapeutic target protein(s), which compound is preferably an inhibitor of said therapeutic target protein.

A further object of the present invention is to provide an inhibitor of said therapeutic target protein(s), and a pharmaceutical composition comprising such inhibitor. Said inhibitor should be preferably a selective inhibitor, i.e. selectively killing or selectively inhibiting the growth of (a) target bacterial pathogen(s) while being substantially inactive towards other bacterial and/or human protein targets.

A further object of the present invention is to provide a method for treatment of the human or animal body, and/or a compound or a pharmaceutical composition for use in such method.


A further object of the present invention is to provide a method for therapy or prophylaxis of a bacterial infection, and/or a compound or a pharmaceutical composition for use in such method, preferably by selectively killing or selectively inhibiting the growth of the pathogenic bacterial species.

A further object of the present invention is to provide a method for therapy or prophylaxis of an acute, chronic or recurrent periodontal disease and/or a compound or a pharmaceutical composition compound for use in in such method.

In the methods for treatment according to the above objects, the route of administration should be preferably topical administration or systemic administration, and the methods are preferably non-surgical methods.

#### SUMMARY OF THE INVENTION

As a solution to the above-formulated problems, the present disclosure provides a compound according to one of the following Formulae I or II,



5

its individual enantiomers, its individual diastereoisomers, its hydrates, its solvates, its crystal forms, its individual tautomers or a pharmaceutically acceptable salt thereof, wherein L, A and R<sup>1</sup> are defined according to the appended claims.

10           The present disclosure further provides a pharmaceutical composition comprising the compound as defined above and a pharmaceutically acceptable excipient.

          The present disclosure further provides a compound as defined above and/or a pharmaceutical composition as defined above for use in a method for treatment of the human or animal body; for use in a method for therapy and/or prophylaxis of a bacterial infection; and for use in a method for therapy and/or prophylaxis of an acute, chronic  
15 or recurrent periodontal disease.

          The present disclosure further provides a crystal comprising a bacterial glutaminyl cyclase (bacQC) selected from PgQC and TfQC, and a co-crystal further comprising a candidate compound, preferably a bacQC inhibitor; as well as methods for preparing said crystal and/or co-crystal.

          The present disclosure further provides methods for identifying a candidate compound which may associate  
20 with the binding pocket of the bacQC, preferably a bacQC inhibitor.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**Fig. 1** shows an amino acid sequence alignment of human QC (hQC, SEQ ID NO: 4) and putative bacterial glutaminyl cyclases (QCs, i.e. glutamine cyclotransferases) from *Porphyromonas gingivalis* (PgQC, SEQ ID NO: 1) **(A)**; an amino acid sequence alignment of further putative QCs from *Prevotella intermedia* (PiQC, SEQ ID NO: 3), *P. gingivalis* (PgQC, SEQ ID NO: 1) and *Tannerella forsythia* (TfQC, SEQ ID NO: 2)) **(B)**; amino acid numbering of the  
25 full-length sequence (SEQ ID NO: 1) of glutaminyl cyclase (i.e. glutamine cyclotransferase) from *P. gingivalis* (PgQC), amino acids 1–333 **(C)**; and amino acid numbering of the full-length sequence (SEQ ID NO: 2) of glutaminyl cyclase (i.e. glutamine cyclotransferase) from *T. forsythia* (TfQC), amino acids 1–333 **(D)**.

**Fig. 2** shows SDS-PAGE of purified recombinant putative bacterial QCs expressed in *E. coli*  
30 Rosetta(DE3)pLysS.

**Fig. 3** shows Lineweaver-Burk plots for PgQC **(A)**, PiQC **(B)** and TfQC **(C)** catalyzed cyclization of H-Gln-AMC.

**Fig. 4** shows exemplary v/S characteristics, Lineweaver-Burk and Eadie-Hofstee plots for PgQC-catalyzed cyclization of H-Gln-AMC in the presence of reference compound MWT-S-00431.

35           **Fig. 5** shows PhoA activity in permeabilized *E. coli* CC118 pGP1-2 cells expressing seqPgQC-PhoA fusion proteins.

**Fig. 6** shows ribbon depiction for three glutaminyl cyclases: PgQC **(A)**; TfQC **(B)**; hQC **(C)**; and overlay **(D)**.

**Fig. 7** shows molecular surfaces for three glutaminyl cyclases in the crystal: PgQC (**A**); TfQC (**B**); and hQC (PDB code 3SI0) (**C**). Surface is colored by lipophilicity (green: more lipophilic, purple: more hydrophilic); the centered hole shows the active site.

**Fig. 8** shows molecular surfaces for PgQC (**A**); TfQC (**B**); and hQC (**C**) in the crystal wherein the hydrophilic areas are highlighted in darker grey (upper figures).

**Fig. 9** shows molecular surfaces for PgQC (**A**); TfQC (**B**); and hQC (**C**) in the crystal wherein the lipophilic areas are highlighted in darker grey (lower figures).

**Fig. 10** shows a comparison of the active sites and molecular surfaces of PgQC and hQC.

## DETAILED DESCRIPTION OF THE INVENTION

### 10 Therapeutic Target Proteins (bacQC)


Socransky et al. (*Journal of Clinical Periodontology*, **1998**, 25 134–144) described that the occurrence in subgingival plaques of a so-called “red complex” consisting of the tightly related group *Tannerella forsythia*, *Porphyromonas gingivalis* and *Treponema denticola* relates strongly to clinical measures of periodontal disease, and in particular to pocket depth and bleeding on probing.

15 A further related complex (so-called “orange complex”) includes members of the *Fusobacterium nucleatum/periodonticum* subspecies, *Prevotella intermedia*, *Prevotella nigrescens* and *Peptostreptococcus micros*. Colonization of healthy periodontal sites by members of the “orange complex” was found to correlate with the occurrence of gingivitis. The bacteria of the “orange complex” furthermore promote the colonization by bacteria of the “red complex”, which in turn are associated with deep pockets and chronic periodontitis.

20 Bacteria of the “red complex” and the “orange complex” secrete a variety of virulence factors. For instance, it was found that *P. gingivalis* secretes cysteine proteases such as gingipain, *P. intermedia* secretes salivary IgA proteases, and *T. forsythia* secretes glycosidases.

The present inventors found surprisingly that about 80% of the secreted proteins bearing a signal peptide in the secretome of the oral pathogens *P. gingivalis*, *T. forsythia*, and *P. intermedia* are cleaved at a Xaa-Gln peptide bond by a signal peptidase. The N-termini of the released proteins contain a pGlu-residue. This implies the existence of glutaminyl cyclases which seem to be essential for growth protein translocation across outer membrane and the growth of said periodontal pathogens.

30 Glutaminyl cyclases (QCs) (EC 2.3.2.5), also referred to as glutamine cyclotransferases, are acyltransferases that catalyze the cyclization of N-terminal glutaminyl residues of proteins to pyroglutamate (pGlu) under release of NH<sub>3</sub>, thus modifying the N-terminus of the peptides:



Two types of QCs (Type I and Type II) have been defined so far. Type I QCs were found in plants and in several pathogenic bacteria and human parasites (Huang et al., *J. Mol. Biol.* **2010**, 401, 374–388). Papaya QC (pQC) is the best-known Type I QC. This enzyme was first discovered in the latex of the tropical plant *Carica papaya* (Messer, M. *Nature* **1963**, 197, 1299). The enzyme exhibits catalytic activity over a broad pH range (pH 3.5–11). X-ray crystallographic analyses revealed that pQC is a hatbox-shaped molecule, consisting of a five-bladed β-propeller

traversed by a central channel (Wintjens, R., Belrhali, H., Clantin, B., Azarkan, M., Bompard, C., Baeyens-Volant, D., Looze, Y., and Villeret, V. *J. Mol. Biol.* **2006**, 357, 457–470). pQC contains a zinc ion but is not inhibited at all by heterocyclic chelators (Zerhouni et al., *Biochim. Biophys. Acta* **1998**, 1387, 275–290), and it is therefore assumed that the zinc has only a structural and stabilizing function. pQC is highly resistant to proteolytic, chemical, and thermal denaturations (Wintjens et al., Zerhouni et al.)

Type II QCs were mainly identified in the neuroendocrine tissues of mammals. Among Type II QCs, the human QC (hQC) is the most extensively studied one, which is known to be important in the maturation of numerous neuropeptides and cytokines in their secretory pathways. In contrast to Type I QCs, hQC is quite susceptible to chemical and thermal denaturation. Schilling et al., 2003 (*J. Biol. Chem.* **2003**, 278, 49773–49779) have shown that hQC was significantly unstable above pH 8.5 and below pH 6.0. hQC adopts an  $\alpha/\beta$  topology (Huang et al. *Proc. Natl Acad. Sci. USA*, **2005**, 102, 13117–13122) and was identified as a metalloenzyme, as suggested by the time-dependent inhibition by the heterocyclic chelators. Inactivated enzyme can be fully restored by the addition of  $Zn^{2+}$  in the presence of equimolar concentrations of EDTA (Schilling et al., 2003). Thus, Type II QCs are metal-dependent transferases, suggesting that the active site bound metal ( $Zn^{2+}$ ) is essential for the catalytic activity, in contrast to the Type I QCs, wherein zinc has only a structural and stabilizing function.

In summary, Type I QCs are generally found in plants, several bacteria and protozoa; they exhibit  $\beta$ -propeller structures; high resistance against proteolysis, heat, and acid; the optimal catalytic activity is at pH 3.5-11; and possess a structural  $Ca^{2+} / Zn^{2+}$  ion.

In contrast, Type II QCs are mainly found in vertebrates; they exhibit  $\alpha/\beta$ -topologies; low resistance against proteolysis, heat, and acid; the optimal catalytic activity is at pH 6.0-8.0; and there is catalytically essential  $Zn^{2+}$  ion. Thus, Type II glutamyl cyclases are zinc-dependent acyltransferases.

The present inventors surprisingly found that Type II QCs are expressed in the oral pathogens *P. gingivalis*, *T. forsythia*, and *P. intermedia*.

The primary structure of the QC protein from *P. gingivalis* (PgQC, SEQ ID NO: 1) has a 25% identity to human QC (hQC, SEQ ID NO: 4). Furthermore, QC from *P. intermedia* (PiQC, SEQ ID NO: 3) and *T. forsythia* (TfQC, SEQ ID NO: 2) were identified, which share an identity to PgQC of 42% and 49%, respectively. Further experimental evidence shows that these enzymes indeed belong to the Type II QC family, as confirmed *inter alia* by pH and ionic strength dependency of the bacQC activity, the inhibition of the QC activity by metal chelators, the folding patterns of all three proteins suggesting an  $\alpha/\beta$  topology as indicated by the CD spectroscopic analysis, and their thermal stability.


The present inventors found that bacterial Type II QCs are expressed in and are essential for the growth of 2 out of 3 periodontitis-causing bacterial species of the “red complex”, as well as at least one bacterial species of the “orange complex”, and are therefore of crucial importance for as a target for the development of a therapeutic inhibitor with antibiotic properties for the treatment of periodontitis diseases and conditions.

Thus, in the context of the present, the therapeutic target proteins are bacterial glutamyl cyclases (bacQCs), wherein a bacQC is defined as a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (also referred to as PgQC), SEQ ID NO: 2 (also referred to as TfQC), SEQ ID NO: 3 (also referred to as PiQC), and an amino acid sequence having a sequence identity of 90% or more to any one of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3.

5 bacQCs can be identified, isolated and purified and used to identify inhibitors capable of selective targeting of periodontitis-inducing pathogens as further described in the examples herein. For the purposes of comparing two or more amino acid sequences, the degree of identity between two amino acid sequences (percentage of “sequence identity”) can be determined by conventional methods, for example, by means of standard sequence alignment algorithms known in the state of the art, such as, for example BLAST (Altschul S.F. et al. *J Mol Biol.* **1990**, 215(3), 403-10).

### Compounds


10 By using the methods for identifying candidate compounds and/or inhibitors disclosed herein, the present inventors have now identified a novel group as a lead structural motif for the design and preparation of potent and therapeutically effective inhibitors of bacterial glutaminy cyclases. Said structural motif is a imidazo[4,5-b]pyridine group as shown below (including the numbering of the ring atoms):



15 This structural motif represents a suitable metal binding group capable of reversibly binding to the  $Zn^{2+}$  ion located in the binding pocket of the bacQCs. Preferably, when the imidazo[4,5-b]pyridine group is substituted at the 6-position of the pyridine ring, a particularly high bacQC inhibitory activity and selectivity can be attained.

More preferably, the group bound to the imidazo[4,5-b]pyridine group is either a benzyl amine or an aromatic sulfonamide, each bound via the N atom to the pyridine ring. In contrast, it was found that using aromatic amides instead provides a weak activity, and these are therefore less preferred. In other words,  $R^a$  and  $R^b$  preferably do not represent together =O.

20 In a further preferred embodiment, the compounds comprise a moiety represented by the following structure E:



E

25 The presence of this moiety enhances the uptake of the inhibitor compounds according to the present invention into the cells of bacteria expressing Type II glutaminy cyclases (such as *P. gingivalis*, *T. forsythia* and *P. intermedia*) which recognize, actively uptake and capture the above porphyrin moiety by means a metal-independent system (e.g., HA2 domain, which is a receptor for both haem and haemoglobin) and/or metal-dependent system (e.g., HusA, which is a haemophore-like porphyrin binding protein capable of recognizing the above group). Thus, conjugating an inhibitor of the general Formula I or II with a moiety represented by structure E provides enhanced,






said alkenyl is independently a linear or branched, open-chained or cyclic C<sub>2-6</sub>, preferably C<sub>2-4</sub>, more preferably C<sub>2</sub> group comprising at least one C=C bond;

said heteroaryl is independently an aromatic, monocyclic or bicyclic, C<sub>1-11</sub>, preferably C<sub>2-8</sub>, more preferably C<sub>4-5</sub> heterocyclic group comprising 1 to 4 ring heteroatoms selected from N, S and O; and

said heteroalkyl is independently a linear or branched, open-chained or cyclic C<sub>1-5</sub>, preferably C<sub>1-3</sub>, more preferably C<sub>1-2</sub> heteroalkyl group comprising 1 to 4 heteroatoms selected from N, S and O.

<3> The compound according to any one of aspects <1> to <2>, which is represented by one the following formulae Ia, IIa, Ib and IIb, preferably Ia:



wherein A is selected from optionally substituted aryl and optionally substituted heteroaryl; and


R<sup>1</sup>, R<sup>a</sup> and R<sup>b</sup> are H.

<4> The compound according to any one of aspects <1> to <3>, wherein R<sup>a</sup> and R<sup>b</sup> are independently selected from <sup>1</sup>H and D.

<5> The compound according to any one of aspects <1> to <4>, wherein either one of R<sup>a</sup> and R<sup>b</sup> is <sup>1</sup>H and the other one is D; or each of them is <sup>1</sup>H; or each of them is D.

<6> The compound according to any one of aspects <1> to <5>, wherein:

A is represented by one of the following structures A-1 to A-7;



wherein Y is selected from O and S; and

5                   $R^2$  to  $R^6$  are each independently selected from the group consisting of H, fluoro, chloro, bromo, iodo, alkyl, aryl, heteroaryl, alkoxy, aryloxy, (aminoalkyl)oxy, (heteroaryl)oxy, amino, (dialkyl)amino, (monoalkyl)amino, (alkyl)(heteroalkyl)amino, (diheteroalkyl)amino, [(alkyl)oxy]carbonyl and haloalkyl, each of which can optionally be further substituted.

10                  <7>                  The compound according to aspect <6>, wherein either:


- (a)  $R^4$ , or
- (b)  $R^3$ , or
- (c)  $R^3$  and  $R^4$

15                  is/are each independently selected from the group consisting of fluoro, chloro, bromo, iodo, alkyl, aryl, heteroaryl, alkoxy, aryloxy, (aminoalkyl)oxy, (heteroaryl)oxy, amino, (dialkyl)amino, (monoalkyl)amino, (alkyl)(heteroalkyl)amino, (diheteroalkyl)amino, [(alkyl)oxy]carbonyl and haloalkyl, each of which can optionally be further substituted;

20                  and the remaining ones of  $R^2$  to  $R^6$  are H.

<8>                  The compound according to any one of aspects <6> to <7>, wherein

25                  at least one of  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  is independently represented by the following structure B:



wherein  $n = 1, 2, 3, 4, 5$  or  $6$ ;

$R^7$  and  $R^8$  are independently selected from alkyl, aryl, heteroalkyl, heteroaryl, carbamimidoyl, formyl, alkylacyl and arylacyl, each of optionally be further substituted and wherein  $R^7$  and  $R^8$  can be optionally joined together to form a carbocyclic or a heterocyclic ring.

5


<9> The compound according to any one of aspects <6> to <8>, wherein:

$R^1$ ,  $R^a$  and  $R^b$  are H; and

10

A is represented by the structure A-1.

<10> The compound according to any one of aspects <1> to <7>, wherein A is substituted by at least one substituent represented by the following structure B:



15

**B**


wherein  $n = 1, 2, 3, 4, 5$  or  $6$ ; and

$R^7$  and  $R^8$  are independently selected from alkyl, aryl, heteroalkyl, heteroaryl, carbamimidoyl, formyl, alkylacyl and arylacyl, each of which can optionally be further substituted and wherein  $R^7$  and  $R^8$  can be optionally joined together to form a carbocyclic or a heterocyclic ring.

20

<11> The compound according to any one of aspects <8> to <10>, wherein  $R^7$  is represented by the following structure E:

25



**E**


wherein M is selected from  $Fe^{2+}$  and  $Fe^{3+}$  or is absent;

30

$R^c$  and  $R^d$  are independently selected from  $-H$ ,  $-CH_3$ ,  $-CH=CH_2$ ,  $-SO_3H$  and  $-CH(OH)CH_2OH$ ; and

X is selected from a covalent bond, an alkylene, aralkylene, heteroalkylene, carbocyclene, heterocyclene, heteroarylene, heteroaralkylene, aminoalkylene, alkylamino and carbonyl-alkylamino group; wherein each of these may have up to 12 carbon atoms and up to 11 heteroatoms in the main chain, and may be substituted by one or more C<sub>1-6</sub> alkyl group(s), C<sub>1-6</sub> heteroalkyl group(s), C<sub>1-6</sub> carbocyclyl group(s), C<sub>1-5</sub> heterocyclyl group(s), C<sub>1-5</sub> heteroaryl group(s), halogen atom(s), hydroxyl group(s), cyano group(s), primary, secondary or tertiary amino group(s), carboxyl group(s) and side chain(s) derived from proteinogenic or non-proteinogenic amino acid(s).

<12> The compound according to aspect <11>, wherein X is represented by the following structure:




**X**

wherein  $m = 0, 1, 2$  or  $3$ , and

R<sup>e</sup> is a side chain derived from a proteinogenic amino acid.

<13> The compound according to any one of aspects <1> to <12>, wherein A is substituted by a substituent represented by the following structure F:




**F**

wherein M is selected from Fe<sup>2+</sup> and Fe<sup>3+</sup> or is absent; and

R<sup>c</sup> and R<sup>d</sup> are independently selected from -H, -CH<sub>3</sub>, -CH=CH<sub>2</sub>, -SO<sub>3</sub>H and -CH(OH)CH<sub>2</sub>OH.

<14> The compound according to aspect <13>, wherein A is as defined according to aspect <6>, and wherein at least one of  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  is represented by the structure F.

<15> The compound according to any one of aspects <1> to <14>, wherein A is substituted by at least one substituent represented by the following structure E1:



10 wherein M is selected from  $Fe^{2+}$  and  $Fe^{3+}$  or is absent;

$R^c$  and  $R^d$  are independently selected from  $-H$ ,  $-CH_3$ ,  $-CH=CH_2$ ,  $-SO_3H$  and  $-CH(OH)CH_2OH$ ; and

X is selected from a covalent bond, O, NH, an alkylene, aralkylene, heteroalkylene, carbocyclene, heterocyclene, heteroarylene, heteroaralkylene, aminoalkylene, alkylamino and carbonyl-alkylamino group; 15  
wherein each of these may have up to 12 carbon atoms and up to 11 heteroatoms in the main chain, and may be substituted by one or more  $C_{1-6}$  alkyl group(s),  $C_{1-6}$  heteroalkyl group(s),  $C_{1-6}$  carbocyclyl group(s),  $C_{1-5}$  heterocyclyl group(s),  $C_{1-5}$  heteroaryl group(s), halogen atom(s), hydroxyl group(s), cyano group(s), primary, secondary or tertiary amino group(s), carboxyl group(s) and side chain(s) derived from 20  
proteinogenic or non-proteinogenic aminoacid(s).

<16> The compound according to any one of aspects <1> to <15>, wherein

A is selected from the group consisting of alkoxyaryl, (alkoxy)(halo)aryl, (alkoxy)heteroaryl, alkylaryl, 25  
alkylheteroaryl, aminoaryl, aminoheteroaryl, arylaryl, arylheteroaryl, (aryloxy)aryl, (aryloxy)heteroaryl, haloaryl, haloheteroaryl, (heteroalkyl)aryl, (haloalkyl)aryl, (heteroaryl)aryl, [(heteroaryl)oxy]aryl, [(aminoalkyl)oxy]aryl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl, each of which can optionally be further substituted.

30 <17> The compound according to any one of aspects <1> to <16>, wherein:


A is selected from the group consisting of 2-alkoxyphenyl, 3-alkoxyphenyl, 4-alkoxyphenyl, 2,3-dialkoxyphenyl, 2,4-dialkoxyphenyl, 2,5-dialkoxyphenyl, 2,6-dialkoxyphenyl, 3,4-dialkoxyphenyl, 3,5-



dialkoxyphenyl, 3,4,5-trialkoxyphenyl, 2,6-dihalo-4-alkoxyphenyl, 2-halo-4-alkoxyphenyl, 3-halo-5-alkoxyphenyl, 4-halo-3-alkoxyphenyl, 2-alkylphenyl, 3-alkylphenyl, 4-alkylphenyl, 3-[(alkyl)(heteroalkyl)amino]phenyl, 3-[(dialkyl)amino]phenyl, 3-[(diheteroalkyl)amino]phenyl, 3-[(monoalkyl)amino]phenyl, 4-[(alkyl)(heteroalkyl)amino]phenyl, 4-[(dialkyl)amino]phenyl, 4-[(diheteroalkyl)amino]phenyl, 4-[(heteroaryl)oxy]phenyl, 4-[(monoalkyl)amino]phenyl, arylphenyl, 2-(aryloxy)phenyl, 3-(aryloxy)phenyl, 4-(aryloxy)phenyl, 2-halophenyl, 3-halophenyl, 4-halophenyl, 2,3-dihalophenyl, 2,4-dihalophenyl, 2,5-dihalophenyl, 2,6-dihalophenyl, 3,4-dihalophenyl, 3,5-dihalophenyl, 2,3,4-trihalophenyl, 2,3,5-trihalophenyl, 3,4,5-trihalophenyl, 2,4,5-trihalophenyl, 2,4,6-trihalophenyl, 3-(haloalkyl)phenyl, 4-(haloalkyl)phenyl, 3-(C<sub>5</sub> monoheteroaryl)phenyl, 4-(C<sub>5</sub> monoheteroaryl)phenyl, 3-(C<sub>4</sub> monoheteroaryl)phenyl, 4-(C<sub>4</sub> monoheteroaryl)phenyl, 3-[(heteroaryl)oxy]phenyl, 4-[[amino(alkyl)]oxy]phenyl, 3-[[amino(alkyl)]oxy]phenyl, naphthyl, phenyl, C<sub>5</sub> monoheteroaryl, C<sub>4</sub> monoheteroaryl, morpholinyl and piperidinyl, each of which can optionally be further substituted.

<18> The compound according to any one of aspects <1> to <17>, wherein:

A is selected from the group consisting of 2-methoxyphenyl, 3-methoxyphenyl, 4-propoxyphenyl, 4-methoxyphenyl, 4-isopropoxyphenyl, 4-benzyloxyphenyl, 3,4-dimethoxyphenyl, 2,3-dihydro-1,4-benzodioxin-6-yl, 2,2-difluoro-1,3-benzodioxol-5-yl, 7-methoxy-1,3-benzodioxol-5-yl, 2,6-difluoro-4-methoxyphenyl, 3-(1-piperidyl)phenyl, 4-morpholinophenyl, [1,1'-biphenyl]-3-yl, [1,1'-biphenyl]-4-yl, 3-phenoxyphenyl, 4-phenoxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3,4,5-trifluorophenyl, 4-(2-pyridyl)phenyl, 4-(2-carbamimidamidoethoxy)phenyl, 4-(2-aminoethoxy)phenyl, 4-(2-morpholinoethoxy)phenyl, phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl and 3-thienyl.

<19> A compound selected from the group consisting of:





The expression "alkyl" as used herein, unless specifically limited, denotes a C<sub>1-12</sub> alkyl group, suitably a C<sub>1-8</sub> alkyl group, e.g. C<sub>1-6</sub> alkyl group, e.g. C<sub>1-4</sub> alkyl group. Alkyl groups may be straight chain or branched. Suitable alkyl groups include, for example, methyl, ethyl, propyl (e.g. n-propyl and isopropyl), butyl (e.g. n-butyl, iso-butyl, sec-butyl and tert-butyl), pentyl (e.g. n-pentyl), hexyl (e.g. n-hexyl), heptyl (e.g. n-heptyl) and octyl (e.g. n-octyl). The term "alkyl" also comprises cycloalkyl groups. The expression "cycloalkyl", unless specifically limited, denotes a C<sub>3-10</sub> cycloalkyl group (i.e. 3 to 10 ring carbon atoms), more suitably a C<sub>3,8</sub> cycloalkyl group, e.g. a C<sub>3-6</sub> cycloalkyl group. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. A most suitable number of ring carbon atoms is three to six.

The expression "heteroalkyl", unless specifically limited, refers to an alkyl group wherein one or more carbon atoms, preferably 1, 2 or 3, are replaced by heteroatoms selected from N, S and O.

The expressions "carbocyclyl" and "carbocyclic", unless specifically limited, denote any ring system in which all the ring atoms are carbon and which contains between three and twelve ring carbon atoms, suitably between three and ten carbon atoms and more suitably between three and eight carbon atoms. Carbocyclyl groups may be saturated or partially unsaturated, but do not include aromatic rings. Examples of carbocyclyl groups include monocyclic, bicyclic, and tricyclic ring systems, in particular monocyclic and bicyclic ring systems. Other carbocyclyl



groups include bridged ring systems (e.g. bicyclo[2.2.1]heptenyl). A specific example of a carbocyclyl group is a cycloalkyl group. A further example of a carbocyclyl group is a cycloalkenyl group.

The expression "aryl", unless specifically limited, denotes a C<sub>6-12</sub> aryl group, suitably a C<sub>6-10</sub> aryl group, more suitably a C<sub>6-8</sub> aryl group. Aryl groups will contain at least one aromatic ring (e.g. one, two or three rings). An example of a typical aryl group with one aromatic ring is phenyl. An example of a typical aryl group with two aromatic rings is naphthyl.

The expressions "heterocyclyl" and "heterocyclic", unless specifically limited, refer to a carbocyclyl group wherein one or more (e.g. 1, 2 or 3) ring atoms are replaced by heteroatoms selected from N, S and O. A specific example of a heterocyclyl group is a cycloalkyl group (e.g. cyclopentyl or more particularly cyclohexyl) wherein one or more (e.g. 1, 2 or 3, particularly 1 or 2, especially 1) ring atoms are replaced by heteroatoms selected from N, S or O. Exemplary heterocyclyl groups containing one hetero atom include pyrrolidine, tetrahydrofuran and piperidine, and exemplary heterocyclyl groups containing two hetero atoms include morpholine and piperazine. A further specific example of a heterocyclyl group is a cycloalkenyl group (e.g. a cyclohexenyl group) wherein one or more (e.g. 1, 2 or 3, particularly 1 or 2, especially 1) ring atoms are replaced by heteroatoms selected from N, S and O. An example of such a group is dihydropyranyl (e.g. 3,4-dihydro-2H-pyran-2-yl-).

The expression "heteroaryl", unless specifically limited, denotes an aryl residue, wherein one or more (e.g. 1, 2, 3, or 4, suitably 1, 2 or 3) ring atoms are replaced by heteroatoms selected from N, S and O, or else a 5-membered aromatic ring containing one or more (e.g. 1, 2, 3, or 4, suitably 1, 2 or 3) ring atoms selected from N, S and O. Heteroaryl groups represent a particular subtype within the general class of "heterocyclyl" or "heterocyclic" groups. Exemplary monocyclic heteroaryl groups having one heteroatom include: five membered rings (e.g. pyrrole, furan, thiophene); and six membered rings (e.g. pyridine, such as pyridin-2-yl, pyridin-3-yl and pyridin-4-yl). Exemplary monocyclic heteroaryl groups having two heteroatoms include: five membered rings (e.g. pyrazole, oxazole, isoxazole, thiazole, isothiazole, imidazole, such as imidazol-1-yl, imidazol-2-yl, imidazol-4-yl); six membered rings (e.g. pyridazine, pyrimidine, pyrazine). Exemplary monocyclic heteroaryl groups having three heteroatoms include: 1,2,3-triazole and 1,2,4-triazole. Exemplary monocyclic heteroaryl groups having four heteroatoms include tetrazole. Exemplary bicyclic heteroaryl groups include: indole (e.g. indol-6-yl), benzofuran, benzthiophene, quinoline, isoquinoline, indazole, benzimidazole, benzothiazole, quinazoline and purine.

The expressions "alkoxyaryl", "carboxyaryl", "cyanoaryl", "haloaryl", "hydroxyaryl" and "heteroaryl", unless specifically limited, denote an aryl residue which is substituted by at least one alkoxy, carboxy, cyano, halo, hydroxy and heteroaryl group, respectively.

The expressions "alkoxyheteroaryl", "carboxyheteroaryl", "cyanoheteroaryl", "haloheteroaryl" and "hydroxyheteroaryl", unless specifically limited, denote a heteroaryl residue which is substituted by at least one alkoxy, carboxy, cyano, halo, and hydroxy group, respectively.

The expression "alk", for example in the expressions "alkoxy", "haloalkyl" should be interpreted in accordance with the definition of "alkyl". Exemplary alkoxy groups include methoxy, ethoxy, propoxy (e.g. n-propoxy), butoxy (e.g. n-butoxy), pentoxy (e.g. n-pentoxy), hexoxy (e.g. n-hexoxy), heptoxy (e.g. n-heptoxy) and octoxy (e.g. n-octoxy). Exemplary haloalkyl groups include fluoroalkyl e.g. CF<sub>3</sub>; exemplary haloalkoxy groups include fluoroalkyl e.g. OCF<sub>3</sub>.

The term "halogen" or "halo" comprises fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).

The terms "hydrogen" or "H" as used herein encompass all isotopes of hydrogen, in particular protium ( $^1\text{H}$ ) and deuterium ( $^2\text{H}$ , also denoted as D)

The term "optionally substituted" refers to optional substitution by one or several groups independently selected from: C<sub>1-6</sub> alkyl, C<sub>1-6</sub> heteroalkyl, C<sub>1-6</sub> carbocyclyl, C<sub>1-5</sub> heterocyclyl and C<sub>1-5</sub> heteroaryl group, each of which may be substituted by one or several halogen atoms and/or hydroxyl groups; a halogen atom; a cyano group; a primary, secondary or tertiary amino group; a hydroxyl group; and a carboxyl group.

#### **Stereoisomers**

All possible stereoisomers of the claimed compounds are included in the present invention.

Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

Where the processes for the preparation of the compounds according to the invention give rise to a mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography.

The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their components enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base, or by salt formation with an optically active base, such as quinine, quinidine, quinoxaline, cinchonine, (S)-phenylethylamine, (1R,2S)-ephedrine, (R)-phenylglycinol, (S)-2-aminobutanol, followed by fractional crystallization and regeneration of the free acid. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.

#### **Polymorph Crystal Forms, Solvates, Hydrates**

Furthermore, some of the individual crystalline forms of the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e. hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention. The compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. In view of the close relationship between the free compounds and the compounds in the form of their salts, hydrates or solvates, whenever a compound is referred to in this context, a corresponding salt, solvate or polymorph is also intended, provided such is possible or appropriate under the circumstances.

#### **Tautomers**

As used herein, the term "tautomer" refers to the migration of protons between adjacent single and double bonds. The tautomerization process is reversible. Compounds described herein can undergo any possible tautomerization that is within the physical characteristics of the compound.

#### **Pharmaceutically Acceptable Salts**

As used herein, the term "pharmaceutically acceptable" embraces both human and veterinary use. For example, the term "pharmaceutically acceptable" embraces a veterinarily acceptable compound or a compound acceptable in human medicine and health care.

Salts, hydrates and solvates of the compounds of Formula I and physiologically functional derivatives thereof which are suitable for use in medicine are those wherein the counter-ion or associated solvent is pharmaceutically acceptable. However, salts, hydrates and solvates having non-pharmaceutically acceptable counter-ions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds and their pharmaceutically acceptable salts, hydrates and solvates.

Suitable salts according to the invention include those formed with either organic and inorganic acids or bases. Pharmaceutically acceptable acid addition salts include those formed from hydrochloric, hydrobromic, sulfuric, nitric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, triphenylacetic, sulfamic, sulfanilic, succinic, oxalic, fumaric, maleic, malic, mandelic, glutamic, aspartic, oxaloacetic, methanesulfonic, ethanesulfonic, arylsulfonic (for example p-toluenesulfonic, benzenesulfonic, naphthalenesulfonic or naphthalenedisulfonic), salicylic, glutaric, gluconic, tricarballylic, cinnamic, substituted cinnamic (for example, phenyl, methyl, methoxy or halo substituted cinnamic, including 4-methyl and 4-methoxycinnamic acid), ascorbic, oleic, naphthoic, hydroxynaphthoic (for example 1- or 3-hydroxy-2-naphthoic), naphthaleneacrylic (for example naphthalenes-acrylic), benzoic, 4-methoxybenzoic, 2- or 4-hydroxybenzoic, 4-chlorobenzoic, 4-phenylbenzoic, benzeneacrylic (for example 1,4-benzenediacylic), isethionic acids, perchloric, propionic, glycolic, hydroxyethanesulfonic, pamoic, cyclohexanesulfamic, salicylic, saccharinic and trifluoroacetic acid. Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases such as dicyclohexylamine and *N*-methyl-*D*-glucamine.

All pharmaceutically acceptable acid addition salt forms of the compounds of the present invention are intended to be embraced by the scope of the present invention.

### Pharmaceutical Compositions

The pharmaceutical composition according to the present invention comprises a compound as described above and a pharmaceutically acceptable excipient.

As used herein, the term "pharmaceutical composition" is intended to encompass a product comprising the claimed compounds in the therapeutically effective amounts, as well as any product that results, directly or indirectly, from combinations of the claimed compounds. As used herein, the term "excipient" refers to a carrier, a binder, a disintegrator and/or a further suitable additive for galenic formulations, for instance, for liquid oral preparations, such as suspensions, elixirs and solutions; and/or for solid oral preparations, such as, for example, powders, capsules, gelcaps and tablets. Carriers, which can be added to the mixture, include necessary and inert pharmaceutical excipients, including, but not limited to, suitable suspending agents, lubricants, flavorants, sweeteners, preservatives, coatings, granulating agents, dyes, and coloring agents.

### Therapeutic Applications

The present disclosure provides a compound, e.g., a compound any one of the above aspects <1>-<19>, and/or a pharmaceutical composition as described above for use in a method for treatment of the human or animal body. The present disclosure also provides a method for treatment of the human or animal body wherein the method comprises administration of a therapeutically effective amount of said compound or composition to a subject in need thereof.

The present disclosure further provides a compound and/or a pharmaceutical composition as described above for use in a method for therapy or prophylaxis of a bacterial infection. The present disclosure also provides a method for therapy or prophylaxis of a bacterial infection wherein the method comprises administration of a therapeutically effective amount of said compound or composition to a subject in need thereof. The bacterial infection is preferably caused by a bacterium that expresses a Type II bacterial glutaminyl cyclase (bacQC). More preferably, the bacterial infection is caused by a bacterium selected from the group consisting of the genera *Porphyromonas*, *Prevotella* and *Tannerella*, preferably selected from the group consisting of the species *Porphyromonas gingivalis*, *Prevotella intermedia* and *Tannerella forsythia*.

The bacQC inhibitor compound or the pharmaceutical composition used in the methods according to the present disclosure preferably selectively kill or selectively inhibit the growth of a bacterium selected from the group consisting of the genera *Porphyromonas*, *Prevotella* and *Tannerella*, preferably selected from the group consisting of the species *Porphyromonas gingivalis*, *Prevotella intermedia* and *Tannerella forsythia*, within a biofilm, whereas the remaining bacteria within the biofilm preferably remain essentially unaffected (i.e. are killed or their growth is inhibited to a significantly smaller extent). Said biofilm is preferably a complex biofilm, more preferably a naturally occurring biofilm, and even more preferably a naturally occurring oral biofilm.

The present disclosure further provides a bacQC inhibitor compound or a pharmaceutical composition for use in a method for therapy or prophylaxis of an acute, chronic or recurrent periodontal disease or condition. The major categories of periodontal diseases and conditions are classified in the groups of dental plaque-induced gingival diseases, chronic periodontitis, aggressive periodontitis, periodontitis as a manifestation of systemic diseases, necrotizing periodontal diseases, abscesses of the periodontium, periodontitis associated with endodontic lesions, peri-implant mucositis, peri-implantitis, and endodontic infections. In the present disclosure, the acute, chronic or recurrent periodontal disease is preferably selected from the group consisting of dental plaque-induced gingival diseases, chronic periodontitis, aggressive periodontitis, periodontitis as a manifestation of systemic diseases, necrotizing periodontal diseases, abscesses of the periodontium, periodontitis associated with endodontic lesions, peri-implant mucositis, peri-implantitis, and endodontic infections. The present disclosure also provides a method for therapy or prophylaxis of an acute, chronic or recurrent periodontal disease which is preferably selected from the group consisting of dental plaque-induced gingival diseases, chronic periodontitis, aggressive periodontitis, periodontitis as a manifestation of systemic diseases, necrotizing periodontal diseases, abscesses of the periodontium, periodontitis associated with endodontic lesions, peri-implant mucositis, peri-implantitis, and endodontic infections, wherein the method comprises administration of a therapeutically effective amount of a bacQC inhibitor compound or a pharmaceutical composition according to the present disclosure to a subject in need thereof. Further acute, chronic or recurrent periodontal diseases are described, e.g., in Armitage, A. *Ann Periodontol* **1999**, *4*, 1-6.

In one embodiment of the present disclosure, the compound or the pharmaceutical composition according to the present disclosure is preferably used in any of the methods described above, wherein the route of administration is topical administration, and/or wherein the method is a nonsurgical method. In another embodiment, the inhibitor compound or the pharmaceutical composition according to the present disclosure is preferably used in any of the methods described above, wherein the route of administration is systemic administration, and/or wherein the method is a nonsurgical method.

The term "subject" as used herein refers to an animal, preferably a mammal, most preferably a human, who is or has been the object of treatment, therapy, prophylaxis, observation or experiment.

The term "therapeutically effective amount" as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

### Protein Crystals

The present disclosure provides crystals of bacterial glutaminyl cyclases (bacQCs).

The atomic coordinates in the crystal structure of PgQC are shown in Table 1 on pages 21–42 of the European patent application EP18158343 filed with the European Patent Office on 23 February 2018, the priority of which is claimed by the present application, and to which hereby reference is made; or alternatively, in the RCSB Protein Database ([www.rcsb.org](http://www.rcsb.org)) under the PDB identification code 6QQL, deposited on 19 February 2019. In one embodiment, the crystal comprising a bacterial glutaminyl cyclase (bacQC) is a crystal comprising a PgQC, the PgQC being a polypeptide comprising the amino acid sequence of SEQ ID NO. 1 or an amino acid sequence having a sequence identity of 90% or more to SEQ ID NO. 1, and preferably having:

- the atomic coordinates according to Table 1 of EP18158343 or 6QQL as mentioned above, or wherein the root mean square deviation from the backbone atoms of the polypeptide chain according to Table 1 of EP18158343 or 6QQL as mentioned above is 2 Å or less, and/or
- a binding pocket defined by residues Gln133; Asp149; Glu182; Asp183; Tyr187; Gly188; Asp189; Asp190; Trp193; Cys194; Asp218; Met219; Phe232; Gly263; Ala264; Leu265; Thr266; Asp267; Val270; Ile284; Tyr286; Asn290; Glu291; His292; Gly293; Phe294; Trp298; His299 of SEQ ID NO: 1, and/or
- the space group  $P3_121$  and unit cell dimensions of  $a = 89.9 \text{ \AA}$ ,  $b = 89.9 \text{ \AA}$ ,  $c = 164.7 \text{ \AA}$ ,  $\alpha = 90^\circ$ ,  $\beta = 90^\circ$  and  $\gamma = 120^\circ$ .

Further preferably, the PgQC crystal diffracts x-rays for determination of atomic coordinates of the crystal to a resolution of between 2.81 and 44.95 Å.

The atomic coordinates in the crystal structure of TfQC are shown in Table 2 on pages 43–91 of the European patent application EP18158343 filed with the European Patent Office on 23 February 2018, the priority of which is claimed by the present application, and to which hereby reference is made; or alternatively, in the RCSB Protein Database ([www.rcsb.org](http://www.rcsb.org)) under the PDB identification code 6QRO, deposited on 19 February 2019.

In another embodiment, the crystal comprising a bacterial glutaminyl cyclase (bacQC) may be a crystal comprising a TfQC, the TfQC being a polypeptide comprising the amino acid sequence of SEQ ID NO. 2 or an amino acid sequence having a sequence identity of 90% or more to SEQ ID NO. 2, and preferably having:

- the atomic coordinates according to Table 2 of EP18158343 or 6QQL as mentioned above, or wherein the root mean square deviation from the backbone atoms of the polypeptide chain according to Table 2 of EP18158343 or 6QQL as mentioned above is 3 Å or less, and/or
- a binding pocket defined by residues His126; Arg130; His135; Glu183; Asp184; Gly186; Thr187; Glu189; Lys195; Pro196; Asp197; Trp199; Asp224; Met225; Gly269; Ala270; Ile271; Val272; Gln276; Tyr277; Ile290; Tyr292; Gln297; Ser 298; Gly299; Phe300; Trp304; His305 of SEQ ID NO: 2, and/or

- the space group  $P 1$  and unit cell dimensions of  $a = 56.1 \text{ \AA}$ ,  $b = 79.2 \text{ \AA}$ ,  $c = 83.1 \text{ \AA}$ ,  $\alpha = 89.9^\circ$ ,  $\beta = 90.0^\circ$  and  $\gamma = 71.9^\circ$ .

Further preferably, the TfQC crystal diffracts x-rays for determination of atomic coordinates of the crystal to a resolution of between 2.10 and 38.28  $\text{\AA}$ .

5 The root mean square deviation from the backbone atoms of the polypeptide chain can be determined as a positional root mean square deviation from the structural coordinates of the equivalent  $C_\alpha$  backbone atoms following structural alignment of the structure to be compared with the structure of the protein according to the present invention and using the program DALI (L. Holm and C. Sander, *Science*, **1996**, vol. 273, 595-602). The term "binding pocket" as used herein includes references to a specific region (or atom) in a molecular entity that is capable of  
10 entering into a stabilizing interaction with another molecular entity. In certain embodiments, the term also refers to the reactive parts of a macromolecule that directly participate in its specific combination with another molecule. In an alternative embodiment, a binding site comprises or is defined by the three-dimensional arrangement of one or more amino acid residues within a folded polypeptide. Most preferably, the binding pocket of the bacQCs described herein is defined, respectively, by the atoms of the residues listed for each of the bacQCs above.

15 In a particular embodiment of the invention, the crystal comprising a bacterial glutaminyl cyclase (bacQC) is a crystal comprising a polypeptide fragment comprising a truncated amino acid sequence of SEQ ID NO. 1 or an amino acid sequence having a sequence identity of 90% or more to a truncated amino acid sequence of SEQ ID NO. 1. Said truncated amino acid sequence of SEQ ID NO. 1 is obtained by deletion of 1 to 132, preferably 1 to 20, more preferably 2 to 10 consecutive amino acids starting from the N-terminus of the amino acid sequence of SEQ ID NO.  
20 1, and/or by deletion of 1 to 34, preferably 1 to 10, more preferably 2 to 5 consecutive amino acids starting from the C-terminus of SEQ ID NO. 1.

In another particular embodiment of the invention, the crystal comprising a bacterial glutaminyl cyclase (bacQC) is a crystal comprising a polypeptide fragment comprising a truncated amino acid sequence of SEQ ID NO.  
25 ID NO. 2. Said truncated amino acid sequence of SEQ ID NO. 2 is obtained by deletion of 1 to 125, preferably 1 to 21, more preferably 2 to 10 consecutive amino acids starting from the N-terminus of the amino acid sequence of SEQ ID NO. 2, and/or by deletion of 1 to 29, preferably 1 to 10, more preferably 2 to 5 consecutive amino acids starting from the C-terminus of SEQ ID NO. 2.

In yet another embodiment, a co-crystal is provided comprising bacQC as described above together with a  
30 candidate compound. The candidate compound is preferably bound to a binding pocket of the bacQC. The candidate compound is further preferably a bacQC inhibitor. Most preferably, the candidate compound is a compound according to one of the Formulae I or II as specified in any one of aspects <1> to <19>.

The crystals and co-crystals according to the present invention are preferably of sufficient quality and size to allow for the determination of the three-dimensional X-ray diffraction structure of a bacterial glutaminyl cyclase to a  
35 resolution of about 1.9  $\text{\AA}$  and to about 2.8  $\text{\AA}$ .

Both crystal structures share an  $\alpha$ - $\beta$  hydrolase fold, that is determined by 8 stranded  $\beta$ -sheet surrounded by 7  $\alpha$ -helices. In both cases the Zn-ion is tetrahedrally coordinated with 2 aspartates and 1 histidine, respectively. The fourth coordination site is occupied by a water molecule, the substrate or a metal binding group as sub-structural part of an inhibitor. These metal interactions of a small group and the Zn ion are essential for the design of an active  
40 compound used as antibacterial agent against the pathogens mentioned herein. Furthermore, the binding sites are

formed by hydrophobic and hydrophilic areas that are different compared to the human enzyme and that are responsible to generate the selectivity for the bacterial enzymes (see Figs. 7–10).

The crystals and co-crystals according to the present invention can be prepared as by batch, liquid bridge, dialysis, vapor diffusion methods, such as hanging or sitting drop vapor diffusion, as further described below.

5 One preferred method for preparing the bacQC crystal as defined above comprises the steps of:

(a) providing a solution comprising a bacQC as defined above, preferably in the presence of 150 mM NaCl, in a suitable buffer such as 50 mM Tris-HCl pH 8.0;

(b) mixing said solution with an equal amount crystallization solution comprising (i) 1 M HEPES pH 8.0, 2 M ammonium sulfate, 3 % (v/v) PEG400 in the case of PgQC; or (ii) 0.1 M sodium acetate pH 4.6, 2 M ammonium sulfate in the case of TfQC; and

10 (c) incubating the obtained mixture under conditions to promote hanging or sitting drop vapor diffusion for a time sufficient to obtain the crystal of the bacQC.

One method for preparing the co-crystal of a bacQC together with a candidate compound comprises the steps:

15 (a) providing a solution comprising a bacQC as defined above, preferably PgQC, and a candidate compound dissolved in 100 mM HCl, in a molar ratio of bacQC:compound = 1:2.3;

(b) mixing said solution with an equal amount crystallization solution comprising 1 M HEPES pH 8.0, 2 M ammonium sulfate, 3 % (v/v) PEG400; and

20 (c) incubating the obtained mixture under conditions to promote hanging or sitting drop vapor diffusion for a time sufficient to obtain the co-crystal of the bacQC and the candidate compound.

Another method for preparing the co-crystal of a bacQC together with a candidate compound comprises the steps:

25 (d) providing a solution as seed stock of harvested and crushed bacQC, preferably TfQC crystal without candidate compound produced as defined above;

(e) providing a solution comprising a bacQC as defined above, and a candidate compound dissolved in 100 mM HCl, in a molar ratio of bacQC:compound = 1:1.2;

30 (f) mixing said solution with an equal amount crystallization solution comprising 1 M Potassium PIPES pH 6.6 or pH 6.8, 32.5 % (v/v) PEG 600, 0,1 M NaCl and 15 % seed stock solution;

(g) incubating the obtained mixture under conditions to promote hanging or sitting drop vapor diffusion for a time sufficient to obtain the co-crystal of the bacQC and the candidate compound.

#### Methods for Identifying Candidate Compounds and/or Inhibitors

The present invention provides a method for identifying a candidate compound which may associate with a binding pocket of a bacQC comprising the following steps:

(a) generating a 3-dimensional model of the respective bacQC using the structural coordinates described in Table 1 of EP18158343 or 6QQL as mentioned above or 2,

(b) analyzing the binding pocket provided by residues Gln133; Asp149; Glu182; Asp183; Tyr187; Gly188; Asp189; Asp190; Trp193; Cys194; Asp218; Met219; Phe232; Gly263; Ala264; Leu265;

Thr266; Asp267; Val270; Ile284; Tyr286; Asn290; Glu291; His292; Gly293; Phe294; Trp298; His299 of SEQ ID NO: 1 according to the coordinates of Table 1 of EP18158343 or 6QQL as mentioned above, or analyzing the binding pocket provided by residues His126; Arg130; His135; Glu183; Asp184; Gly186; Thr187; Glu189; Lys195; Pro196; Asp197; Trp199; Asp224; Met225; Gly269; Ala270; Ile271; Val272; Gln276; Tyr277; Ile290; Tyr292; Gln297; Ser298; Gly299; Phe300; Trp304; His305 of SEQ ID NO: 2 according to the coordinates of Table 2 of EP18158343 or 6QQL as mentioned above;

- (c) performing computer modeling analysis to identify a candidate compound which may associate with a binding pocket of the respective bacQC.

Preferably, the method further comprises:


- (d) verifying *in vitro* whether the candidate compound reduces the catalytic activity of the bacQC, thereby classifying a candidate compound that reduces the catalytic activity of the bacQC as a bacQC inhibitor.

Verifying whether a candidate compound reduces the catalytic activity of the bacQC can be performed, for example, by a method for identifying an inhibitor of the bacQC comprising the following steps (d1)–(d5):

- (d1) providing a composition comprising a substrate of the bacQC and the bacQC;  
 (d2) providing a candidate compound identified in (c);  
 (d3) contacting the candidate compound with the composition;  
 (d4) monitoring the catalytic activity of the bacQC;  
 (d5) classifying the candidate compound as an inhibitor of the bacQC based on the effect of the candidate compound on the catalytic activity of bacQC, wherein a candidate compound that reduces the catalytic activity of the bacQC is classified a bacQC inhibitor.

Said composition (in step d1) can be an aqueous solution, preferably comprising suitable buffer and/or salt components. Said substrate is preferably a peptide or peptide derivative comprising a glutamine residue at its N-terminus. Said substrate is preferably labeled, more preferably isotopically labeled, most preferably a fluorogenic substrate. The fluorogenic substrate preferably undergoes a change in fluorescence intensity after being converted in the course of a reaction catalyzed by a bacQC.

A suitable fluorogenic substrate for monitoring bacQC activity is H-Gln-AMC, as described in Schilling, S., Hoffmann, T., Wermann, M., Heiser, U., Wasternack, C., and Demuth, H.-U. *Anal. Biochem.* **2002**, 303, 49-56 (Schilling *et al.*, 2002), as shown in the following scheme:



The candidate compound can be contacted prior to, simultaneously with or after the addition of the remaining components of the composition of step (d1). The candidate compound is preferably provided in solution, more preferably as a DMSO solution.



The conversion of the substrate is monitored over time, e.g., by monitoring the emission of the fluorophore generated by the cleavage of a fluorogenic substrate. bacQC activity can be determined from a standard curve of the AMC under assay conditions.

The bacQC catalytic activity can be determined using different concentration of substrate, bacQC and/or candidate compound. Suitable measures for the bacQC catalytic activity are, e.g., inhibitory constants ( $K_i$ ), 50% residual activity (RA) in the presence of a given concentration of a candidate compound, and/or  $IC_{50}$  values.

The present invention further provides a method for identifying a candidate compound which associates with a binding pocket of a bacQC, the method comprising the following steps:

- (a) generating a 3-dimensional model of a co-crystal comprising bacQC as described above together with a candidate compound;
- (b) analyzing the distances between the atoms of the candidate compound and the atoms of the binding pocket provided by residues Gln133; Asp149; Glu182; Asp183; Tyr187; Gly188; Asp189; Asp190; Trp193; Cys194; Asp218; Met219; Phe232; Gly263; Ala264; Leu265; Thr266; Asp267; Val270; Ile284; Tyr286; Asn290; Glu291; His292; Gly293; Phe294; Trp298; His299 of SEQ ID NO: 1, or the atoms of the binding pocket atoms of by residues XXXX His126; Arg130; His135; Glu183; Asp184; Gly186; Thr187; Glu189; Lys195; Pro196; Asp197; Trp199; Asp224; Met225; Gly269; Ala270; Ile271; Val272; Gln276; Tyr277; Ile290; Tyr292; Gln297; Ser 298; Gly299; Phe300; Trp304; His305 of SEQ ID NO: 2, to identify a candidate compound that associates with the binding pocket of the bacQC.

Preferably, the method further comprises:

- (c) verifying *in vitro* whether the candidate compound reduces the catalytic activity of the bacQC, thereby classifying a candidate compound that reduces the catalytic activity of the bacQC as a bacQC inhibitor.

Verifying whether a candidate compound reduces the catalytic activity of the bacQC can be performed, for example, by a method for identifying an inhibitor of the bacQC comprising the following steps (c1)–(c5):

- (c1) providing a composition comprising a substrate of the bacQC and the bacQC;
- (c2) providing a candidate compound identified in (b);
- (c3) contacting the candidate compound with the composition;
- (c4) monitoring the catalytic activity of the bacQC;
- (c5) classifying the candidate compound as an inhibitor of the bacQC based on the effect of the candidate compound on the catalytic activity of bacQC, wherein a candidate compound that reduces the catalytic activity of the bacQC is classified a bacQC inhibitor.

## EXAMPLES

### I. Identification and Preparation of putative bacterial glutaminyl cyclases (bacQC)

#### a) Identification

Bioinformatics analysis of the secretome of the oral pathogens *P. gingivalis*, *T. forsythia*, and *P. intermedia* (5 (<http://www.oralgen.lanl.gov/>) showed that about 80% of the secreted proteins bearing a signal peptide are cleaved at a Xaa-Gln peptide bond by the signal peptidase. The N-termini of the released proteins contain a pGlu-residue. This implies the existence of glutaminyl cyclases which seem to be essential for growth protein translocation across outer membrane and the growth of periodontal pathogens.

**Fig. 1** shows an amino acid sequence alignment of human QC (hQC, SEQ ID NO: 4) and putative bacterial 10 QC from *P. gingivalis* (PgQC, SEQ ID NO: 1) (**A**), and an amino acid sequence alignment of further putative QC *P. intermedia* (PiQC, SEQ ID NO: 3) and *T. forsythia* (TfQC, SEQ ID NO: 2) and *P. gingivalis* (PgQC, SEQ ID NO: 1) (**B**). Putative PgQC possesses a 25% identity to human QC. Furthermore, putative TfQC exhibits a 49% identity to PgQC and QC from *P. intermedia* possess a 42% identity to PgQC. Grey underlined cysteine residues reflects disulfide bridges in hQC which is missing in PgQC. Bold sequences in human QC reflects highly conserved residues 15 of Type II QC. Grey sequences described putative signal sequences of PgQC and hQC Furthermore the typical metal binding motif Asp-Glu-His is presented in bold and underlined letters. A putative metal binding motif was also identified in TfQC and PiQC (B, bold letters). The alignments were prepared using program Clustal Omega at EMBL-EBI net; (\*) indicates positions which have a single, fully conserved residue, (:) indicates conservation between groups of strongly similar properties, (.) indicates conservation between groups of weakly similar properties 20 (<http://www.ebi.ac.uk/Tools/msa/clustalo/>).

BLAST analysis revealed an open reading frame (ORF) encoding putative QC protein in *P. gingivalis* (WP\_005874301). The primary structure of this putative QC protein shows a 25% identity to human QC. Furthermore, putative QC proteins were also identified in the genome of the oral pathogens *P. intermedia* (WP\_014709208) and *T. forsythia* (WP\_014225037) which shares a 42% or 49% identity to putative QC from *P. 25 gingivalis* (Fig. 1). As shown by the amino acid alignment, conserved residues of human QC seem to be different in bacterial QCs from those conserved cysteine residues which form disulfide bound in human and other Type II QCs are presumably not presence in all three putative bacterial QC. However, highly conserved metal binding motif Asp144, Glu184 (Asp) and His322 of Type II QC (Wintjens *et al.*, 2006) seem to be present in bacterial putative QC which could represent the catalytic center. The primary structures of these proteins may provide an indication that 30 these proteins are actual QCs.

#### b) Preparation

**Fig. 2** shows SDS-PAGE of purified recombinant putative bacterial QCs expressed in *E. coli* Rosetta(DE3)pLysS and purified as described in detail below. Therefore, 30 µg purified protein were loaded to 12% SDS-PAGE and visualized by coomassie staining, lane 1, PageRuler Broad Range unstained (ThermoFisher 35 Scientific), lane 2, HisPgQC, lane 3, HisPiQC and lane 5, HisTfQC. All three putative bacterial QCs possess a theoretical molecular mass of ≈ 37 KDa.

#### aa) Host strains and media

*E. coli* strain DH5α or XL-1 blue (Stratagene) were used for cloning procedures. *E. coli* Rosetta(DE3)pLysS (Novagene) was used for protein expression. The alkaline phosphatase activity assay was performed in the CC118

pGP1-2 strain (Tabor, S. and Richardson, C. C. *Proc. Natl. Acad. Sci. U.S.A.* **1985**, 82, 1074-1078; Manoil, C., J. J. Mekalanos and Beckwith, J. *J. Bacteriol.* **1990**, 172(2), 515-518). All *E. coli* strains were grown in Luria-Bertani medium as indicated at 20°C, 30°C or 37°C. Antibiotics (ampicillin [50 to 125 mg/liter], chloramphenicol [15 to 30 mg/liter], and kanamycin [25 mg/liter]) were added where appropriate. For preparation of solid media 1.5 % agar (Roth) was added to corresponding broth.

**bb) Molecular cloning of plasmid vectors encoding the bacterial QCs**

All cloning procedures were performed applying standard molecular biology techniques. For protein expression, open reading frames (ORFs) of *PgQC* (SEQ ID NO: 1, putative QC from *P. gingivalis*), *PiQC* (SEQ ID NO: 3 putative QC from *P. intermedia*) and *TfQC* (SEQ ID NO: 2, putative QC from *T. forsythia*) were amplified using synthesized DNA sequences purchased from Eurofins Genomics as templates in a PCR to introduce a *NheI*/*NdeI* restriction site essential for direct cloning into the vector pET28a(+) (Novagen). For the construction of a *PgQC*-PhoA fusion protein, putative *pgQC* with predicted signal sequence was subcloned into pET26b(+) via *NheI*/*XhoI* restriction site using primer pair *seqpgQC NdeI* (forward) and *seqpgQC XhoI* reverse. Furthermore, *pgQC* with native signal sequence including a ribosome binding site of a pET26b(+) vector was amplified using primer pair *seqpgQC RBS NotI* (forward) and *seqpgQC XbaI* (reverse) to clone into the *phoA* expression vector pECD637. All Primers for cloning were purchased from Metabion and described in Table 1.

Table 1. Oligonucleotides used for cloning of bacQC constructs

SEQ ID NO:	Primer	Sequence (5' → 3')
5	<i>pgQC NdeI</i> (forward)	AAA <u>CAT ATG</u> AAC GGC AAT AAC ACA AGT GAA
6	<i>pgQC NheI</i> (reverse)	TTT <u>GCT AGC</u> TCA GTG TGA AGC GGC TTT
7	<i>piQC NdeI</i> (forward)	TTT <u>CAT ATG</u> AAA GGA AAA TCG TCT AAC
8	<i>piQC NheI</i> (reverse)	ATG <u>CTA GCT</u> TAC ATG CTG TAA AGC AC
9	<i>tfQC NdeI</i> (forward)	TCA <u>CAT ATG</u> GGT CAG AAA AAT ACG ACA
10	<i>tfQC NheI</i> (reverse)	ATG <u>CTA GCT</u> TAT TTC TCA TTA TAA ATC AC
11	<i>seqpgQC NdeI</i> (forward)	AAA <u>CAT ATG</u> AAA AGA CTG ATA ACA ACA GGA GCA GCC TTT CTA CTG GCT GCT ACA CTC TCT GCC TGC AAC GGC AAT AAC ACA AGT GAA ACG
12	<i>seqpgQC XhoI</i> (reverse)	TTT <u>CTC GAG</u> GTG TGA AGC GGC TTT CAC
13	<i>seqpgQC RBS NotI</i> (forward)	TGG <u>CGG CCG</u> CTA AGA AGG AGA
14	<i>seqpgQC XbaI</i> (reverse)	TTT <u>TCT AGA</u> GTG TGA AGC GGC TTT CAC

**cc) Expression of bacterial QC as His Tag fusion protein or as PhoA fusion protein**

The expression vector pET28a(+):*pgQC* was transformed in *E. coli* Rosetta(DE3)pLysS. Bacteria were grown in Luria-Bertani medium containing kanamycin (25 µg/ml) and chloramphenicol (15 µg/ml) at 37°C until the cell density reached an OD 600 ~ 0.6. The cultures were induced with 0.4 mM isopropyl β-D-1-thiogalactopyranoside and a 2% (v/v) ethanol volume was added followed by an incubation time for 16 h at 20°C. Cultures were harvested by centrifugation at 4°C and 3900 g for 30 min and cell pellets were storage at -20°.

For expression of *seqPgQC*-PhoA fusion protein, recombinant vector pECD637::*seqpgQC* was transformed into CC118 (lacking e.g. *phoA* gene) along with helper plasmid pGP1-2. Cultures were inoculated at 30°C overnight. Furthermore overnight cultures were diluted into fresh Luria-Bertani media to a final optical density (OD600) ~0.4

followed by an incubation at 42°C for 20 min to induce expression of  $_{seq}$ PgQC-PhoA fusion proteins. Then cultures were inoculated for further 2 h at 30°C. Finally optical density OD600 was determined using spectrophotometer (BioRad) and 200  $\mu$ l of cultures were harvested by centrifugation at 4°C and 16000 g for 15 min for determination of PhoA activity.

#### 5 **dd) Purification of bacterial QCs**

Cell pellet of 500 ml culture were resuspended in 20 ml buffer consists of 50 mM Tris-HCl, 150 mM NaCl pH 8.0, 10  $\mu$ g/ml DNase and protease inhibitor cocktail mix (complete mini tablets, EDTA-free, Roche). Cells were disrupted by passing through French Press (Thermo Scientific, Waltman, MA, USA) for 3-4 times. Cell debris was removed by centrifugation at 4°C and 30000 g for 30 min. Supernatant was 1:2 diluted with equilibration buffer and  
10 loaded on 5 ml HisTrap column (GE Healthcare). The column was equilibrated with 50 mM Tris-HCl containing 150 mM NaCl pH 8.0. After washing with several column volumes of equilibration buffer and at least with 20 mM imidazole protein were eluted using multiple step gradients, reaching a final concentration of 250 mM imidazole, whereas majority of pure protein was already eluted with approximately 100 mM imidazole. All bacQC containing fractions were pooled, concentrated with Vivaspin 20 (Sartorius AG) and applied to a HiPrep 26/10 desalting column  
15 (GE, Healthcare), which was equilibrated with 50 mM Tris-HCl, 150 mM NaCl pH 8.0. The purification was analyzed by SDS-PAGE and the protein content was determined by absorption at 280 nm using NanoDrop 2000 spectrophotometer (Thermo Scientific) or according to the methods of Bradford or Gill and von Hippel (Bradford, M. M. 1976 Anal Biochem 72, 248-254; Gill, S.C. and von Hippel, P.H. 1989 Anal Biochem 182, 319-326). Finally purified recombinant fusion bacQC proteins were shock-frozen in liquid nitrogen and stored at -80°C or glycerol was  
20 added to a final concentration of 50 % and storage at -20°C. His Tag of N-terminal fusion proteins were removed using 1 Unit Thrombin per 1 mg fusion protein (Thrombin cleavage Capture Kit, Novagen) in presence of 20 mM Tris-HCl, 150 mM NaCl, 2.5 mM  $CaCl_2$  at pH 8.0 followed by an incubation for 16 h at 4°C. Thrombin was removed through binding to Steptavidin Agarose (Thrombin cleavage Capture Kit, Novagen) and bacQC proteins without HisTag were recovered by spin-filtration. After further desalting step using HiPrep (26/10) bacQC fractions were  
25 pooled and concentrated with Vivaspin 20 (Sartorius AG). Finally recombinant bacQC in 50 mM Tris-HCl, 150 mM NaCl pH 8.0 was shock-frozen in liquid nitrogen and storage at -80°C or glycerol was added to a final concentration of 50 % and storage at -20°C. PiQC was expressed and purified in the same way like PgQC. TfQC was expressed in the same way like PgQC and purified using HiTrap Talon column (GE, Healthcare).

Conclusions: All putative bacterial QC were expressed in *E. coli* Rosetta(DE3)pLysS without signal  
30 sequence as N-terminal His Tag fusion proteins and purified to homogeneity via affinity chromatography. 16 – 40 mg recombinant pure His-Tag fusion proteins were isolated from approximately 500 ml of induced *E. coli* cultures. Subsequently, His-tag of fusion proteins was cleaved by thrombin followed by enzymatic characterization of these putative bacterial QCs.

## II. Protein Crystallization

### 35 **a) PgQC Crystallization**

Crystals of crystallographic quality were obtained from PgQC expressed and purified as described above. PgQC was crystallized at a concentration of 90  $\mu$ M (2.3 mg/ml) within 40 days at 15 °C using hanging drop vapor diffusion technique. In a drop, 1  $\mu$ L protein solution was mixed with an equal volume of crystallization buffer

consisting of 0.1 M HEPES pH 8.0, 3 % (v/v) PEG 400 and 2 M  $(\text{NH}_4)_2\text{SO}_4$ . For the crystallization process, the protein-containing drop was placed in vapor equilibration with 500  $\mu\text{L}$  crystallization buffer included in a reservoir.

Prior to X-ray measurement, crystals were cryoprotected by rapid soaking in crystallization buffer containing 18 % (v/v) glycerol and subsequently flash frozen at  $-180^\circ\text{C}$ . Data from a diffracting single crystal were collected in-house using a CCD detector (SATURN 944+, Rigaku Europe) mounted on a copper rotating-anode source (RA Micro 007, Rigaku Europe). Afterwards collected diffraction data were processed, scaled and merged using XDSGUI. The measured PgQC crystals belong to the trigonal space group  $P3_121$  with the cell constants  $a = 89.9 \text{ \AA}$ ,  $b = 89.9 \text{ \AA}$ ,  $c = 164.7 \text{ \AA}$ , and  $\alpha = 90^\circ$ ,  $\beta = 90^\circ$ ,  $\gamma = 120^\circ$ . They contain two molecules of PgQC in the asymmetric unit and diffract to  $2.8 \text{ \AA}$ .

The initial phases for the PgQC structure were obtained by molecular replacement using the program PHASER MR from the CCP4 crystallographic suite and the search model PgQC with PQ 50, in which some cycles of manual rebuilding using the program COOT and maximum-likelihood refinement using REFMAC5 were carried out. The model was refined to an  $R_{\text{work}}$  value of 0.2428 and an  $R_{\text{free}}$  value of 0.30404. To obtain a final PgQC model, repeating cycles of manual rebuilding and refinement are sufficient.

### b) TfQC Crystallization

Crystals of crystallographic quality were obtained from TfQC expressed and purified as described above. The Protein could be crystallized at a concentration of 9.91 mg/mL (279  $\mu\text{M}$ ) within 91 days at  $15^\circ\text{C}$  using sitting drop vapor diffusion technique. Therefore, 200 nL protein was mixed with an equal volume of crystallization buffer consisting of 2 M  $(\text{NH}_4)_2\text{SO}_4$  and 0,1 M Sodium acetate pH 4.6, in a drop staying in contact by vapor diffusion with a reservoir containing 55  $\mu\text{L}$  of crystallization buffer.

Prior to X-ray measurement, crystals were cryoprotected by rapid soaking in crystallization buffer containing 25 % (v/v) ethylene glycol and subsequently flash frozen at  $-180^\circ\text{C}$ . The following data from a diffracting single crystal were collected in-house using a CCD detector (SATURN 944+, Rigaku Europe) mounted on a copper rotating-anode source (RA Micro 007, Rigaku Europe).

The obtained diffraction data were processed, scaled and merged using the program XDSGUI. TfQC crystals belong to the triclinic space group  $P1$  with the cell constants  $a = 56.1 \text{ \AA}$ ,  $b = 79.2 \text{ \AA}$ ,  $c = 83.1 \text{ \AA}$ , and  $\alpha = 89.9^\circ$ ,  $\beta = 90^\circ$ ,  $\gamma = 71.9^\circ$ . They contain four molecules of TfQC in the asymmetric unit and diffract to  $2.1 \text{ \AA}$ .

The initial phases of the estimated TfQC structure were obtained by molecular replacement using PHASER MR from the CCP4 crystallographic suite. To these solution strategy a suitable search model must be generated, because at these time point no model of TfQC existed. This model was prepared from an initial one of PgQC with PQ 50 by side chain pruning using the Program SCULPTOR from the PHENIX suite. The final TfQC model was obtained after repeating cycles of manual rebuilding using the program COOT and maximum-likelihood refinement using PHENIX.REFINE. It was refined to an  $R_{\text{work}}$  value of 0.1938 and an  $R_{\text{free}}$  value of 0.2404.

### III. Fluorometric Assay for Glutaminyl Cyclase Activity

QC activity was evaluated using H-Gln-AMC as the substrate (as previously described in Schilling *et al.*, 2002).

The assay consists of varying concentration of the fluorogenic substrate and 0.5 U pyroglutaminyl aminopeptidase in 50 mM Tris-HCl, 50 mM NaCl at pH 8.0. After 10 minute incubation time at  $30^\circ\text{C}$  reaction was

initiated by addition of bacQC to a final volume of 125  $\mu$ l reaction mixture. The excitation/emission wavelength was 380/460 nm. bacQC activity was determined from a standard curve of the fluorophore AMC under assay conditions. All determinations were carried out in 96well microtiter plates (Fisher Scientific) at 30°C using the FluoStar Optima (BMG Labtech). The kinetic data were evaluated using GraFit software (Version 7, Erithacus software Ltd., Horley, UK).

**Fig. 3** shows Lineweaver-Burk plots for PgQC (**A**), PiQC (**B**) and TfQC (**C**) catalyzed cyclization of H-Gln-AMC. The inset shows a secondary plot of the obtained slopes of the Lineweaver-Burk evaluation. bacQC activity measurement carried out in 50 mM Tris-HCl, pH 8.0 and 50 mM Tris-HCl at 30 °C. The kinetic data were evaluated using GraFit software (Version 7, Erithacus software Ltd., Horley, UK). Enzymatic parameters of bacterial QC were determined (Table 2), which differ from those of hQC (Schilling, S., Manhart, S., Hoffmann, T., Ludwig, H.-H., Wasternack, C., and Demuth, H.-U. *Biol. Chem.* **2003**, *384*, 1583-1592).

*Table 2. Kinetic parameters for the conversion of H-Gln-AMC by bacterial QC. Determination of kinetic parameters was carried out in 50 mM Tris-HCl pH 8 and 50 mM NaCl at 30 °C.*

Enzyme	$K_m$ [ $\mu$ M]	$k_{cat}$ [ $s^{-1}$ ]	$k_{cat}/K_m$ [ $mM^{-1} s^{-1}$ ]
PgQC	510.94 $\pm$ 13.3	4.71 $\pm$ 0.22	9.24 $\pm$ 0.28
PiQC	645.33 $\pm$ 7.4	8.51 $\pm$ 0.37	13.18 $\pm$ 0.05
TfQC	1091.67 $\pm$ 34.36	4.49 $\pm$ 0.22	4.1 $\pm$ 0.14

Conclusions: Purified recombinant proteins were tested for enzymatic activity using fluorometric assay with H-Gln-AMC as substrate. H-Gln-AMC as substrate was turned over by these bacterial proteins resulted in an increase of RFU and therefore an increasing reaction rate (Fig. 3). The affinity for H-Gln AMC as substrate is, in the case of PgQC and PiQC, approximately tenfold lower than that of hQC for this substrate. The  $K_m$  value of TfQC is actually 20-fold higher than the  $K_m$  value of hQC. Furthermore, the efficiency of bacterial proteins seems to be similar to that of hQC whereat PiQC possesses a twofold higher turnover number comparing PgQC or TfQC.

#### IV. Inhibitor Assay for Bacterial Glutaminyl Cyclase Activity

For inhibitor testing, the sample composition was the same as described above, except for the addition of the putative inhibitory compound. This resulted in presence of 1% or 2% (v/v) DMSO in reaction mixture. Inhibitory constants were determined using different concentration of H-Gln-AMC varying from  $1/4 K_m$  –  $2 K_m$ . Final concentration of bacterial QC was in a range between 25 nM – 50 nM. The inhibitory constant was evaluated by fitting the set of progress curves to the general equation for competitive inhibition using GraFit software (Version 7, Erithacus software Ltd., Horley, UK).

**Fig. 4** shows exemplary v/S characteristics, Lineweaver-Burk and Eadie-Hofstee plots for PgQC catalyzed cyclization of H-Gln-AMC (**A**) in presence of ( $\bullet$ ) 1  $\mu$ M, ( $\square$ ) 0.5  $\mu$ M, ( $\blacksquare$ ) 0.25  $\mu$ M, ( $\triangle$ ) 0.125  $\mu$ M and ( $\blacktriangle$ ) 0.063  $\mu$ M of reference compound MWT-S-00431 ((3,5-dichlorophenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone). ( $\circ$ ) represents reaction without inhibitor. Determinations were carried out in 50 mM Tris-HCl, 50 mM NaCl pH 8.0 and 1% (v/v) DMSO at 30°C. The kinetic parameters shown in Table 3 were obtained.

Table 3. Kinetic parameters for the inhibition of the conversion of H-Gln-AMC by PgQC in the presence of reference compound MWT-S-00431.








Parameter	Value	Std. Error
$V_{max}$ [ $\mu\text{M min}^{-1}$ ]	4.41161	$1.0569 \cdot 10^{-1}$
$K_m$ [M]	$6.45485 \cdot 10^{-4}$	$3.14087 \cdot 10^{-5}$
$K_i$ [M]	$1.03698 \cdot 10^{-7}$	$3.31239 \cdot 10^{-9}$













#### V. Inhibition of Glutaminyl Cyclases by the Compounds

The following compounds were synthesized as described in the Description of synthetic methods below.









- 5 Average  $K_i$  values for the inhibition of PgQC (isolated and purified as described above), TfQC, PiQC and hQC were measured using the above inhibitor assay and are shown in.  $K_i$  refers to the average  $K_i$  values measured as described above, and  $\text{Std}(K_i)$  refers to the standard deviation of  $K_i$ .

Table 4. Inhibition of PgQC, TfQC, PiQC and hQC by bacQC inhibitors.

Compound Structure	Example No.	PgQC	TfQC	PiQC	hQC
		$K_i$ [nM]	$K_i$ [nM]	$K_i$ [nM]	$K_i$ [nM]
	1	$1945 \pm 318$	$8255 \pm 361$	$9400 \pm 325$	$8800 \pm 127$
	2	$149 \pm 4$	$1400 \pm 156$	$1945 \pm 148$	$1280 \pm 71$
	3	$157 \pm 6$	n.d.	n.d.	n.d.
	4	$53 \pm 1$	n.d.	n.d.	$655 \pm 27$
	5	$106 \pm 13$	n.d.	n.d.	$769 \pm 153$
	6	$77 \pm 2$	n.d.	n.d.	$599 \pm 40$
	7	$83 \pm 3$	n.d.	n.d.	n.d.

Compound Structure	Example No.	PgQC	TfQC	PiQC	hQC
		$K_i$ [nM]	$K_i$ [nM]	$K_i$ [nM]	$K_i$ [nM]
	8	185 ± 11	n.d.	n.d.	1870 ± 78
	9	442 ± 71	n.d.	n.d.	n.d.
	10	395 ± 5	n.d.	n.d.	n.d.
	11	139 ± 4	n.d.	n.d.	n.d.
	12	44 ± 1	680 ± 45	728 ± 35	543 ± 20
	13	133 ± 6	n.d.	n.d.	556 ± 28
	14	53 ± 2	358 ± 64	542 ± 44	431 ± 19
	15	34 ± 2	n.d.	n.d.	n.d.
	16	30 ± 2	317 ± 52	815 ± 4	1067 ± 203
	17	14 ± 0.1	123 ± 16	349 ± 17	455 ± 14
	18	86 ± 5	n.d.	n.d.	n.d.
	19	15 ± 0.1	n.d.	n.d.	n.d.



Compound Structure	Example No.	PgQC	TfQC	PiQC	hQC
		$K_i$ [nM]	$K_i$ [nM]	$K_i$ [nM]	$K_i$ [nM]
	20	42 ± 4	n.d.	n.d.	n.d.
	21	19 ± 1	n.d.	n.d.	n.d.
	22	30 ± 1	n.d.	n.d.	n.d.
	23	65 ± 13	n.d.	n.d.	n.d.
	24	67 ± 1	n.d.	n.d.	n.d.
	25	38 ± 3	n.d.	n.d.	n.d.
	26	33 ± 1	n.d.	n.d.	n.d.
	27	60 ± 2	n.d.	n.d.	n.d.

**Conclusion:** All of the compound according to the present invention exhibit inhibitory activity against bacterial glutaminyl cyclases. The above results show that the compounds and/or pharmaceutical compositions are useful in the treatment of periodontal and related diseases. In particular, the compounds and/or pharmaceutical compositions are capable of selectively targeting pathogens which induce a periodontal disease (*P. gingivalis*, *T. forsythia* and *P. intermedia*) while at the same time being essentially inert with respect to the homologous to the human enzyme.

Furthermore, it was found that when the rest of the naturally occurring biofilm should be substantially preserved. Even more preferably, the compounds and/or pharmaceutical compositions should exhibit high in vivo activities against the targeted pathogens.

Furthermore, it was found that when the said pathogens are embedded within a biofilm (e.g., a complex biofilm, a naturally occurring biofilm or a naturally occurring oral biofilm), the remaining bacteria within the biofilm preferably remain essentially unaffected the compounds according to the present invention (i.e. are killed or their growth is inhibited to a significantly smaller extent).

5 As can be seen from the experimental data above, a particularly high inhibitory activity can be achieved when the imidazo[4,5-b]pyridine core is substituted at the 6-position (i.e. according to Formula I, like in Example 2), in contrast to substitution at the 5-position (i.e. according to Formula II, like in Example 1). Nevertheless, in both cases significant bacQC inhibitory activity and selectivity for PgQC over hQC human enzyme is observed (Table 5).

Table 5. Comparison of inhibition parameters of the compounds from Examples 1 and 2

Target Protein	$K_i$ [ $\mu$ M]		relative inhibitory activity [ $K_i$ (Example 1)]/[ $K_i$ (Example 2)]
	Example 1	Example 2	
PgQC	1.95	0.15	13
PIQC	9.4	1.95	4.8
TfQC	8.3	1.4	5.9
hQC	8.8	1.28	6.9

10 Finally, in view of the relatively high degree of homology between PIQC and the other two bacQCs (as shown in Fig. 1), it that the compounds identified as inhibitors of PgQC and/or TfQC by using the methods of the present invention can also be expected to exhibit a significant PIQC activity (as evidenced by the experimental data in Table 6 above).

#### VI. Determination of $_{seq}$ QC-PhoA Activity

15 **Fig 5.** shows the PhoA activity in permeabilized *E. coli* CC118 pGP1-2 cells expressing  $_{seq}$ PgQC-PhoA fusion proteins. PgQC with native putative signal sequence was cloned in pECD637 create a  $_{seq}$ PgQC-PhoA fusion protein. Resulted vector was transformed into *E. coli* strain CC118 pGP1-2. The expression of fusion protein was initiated by incubation of the culture at 42°C for 20 min. The PhoA activity of the induced culture was determined as described previously (Pribyl, T., *Topologie des CzcCBA-Efflux-Komplexes aus Ralstonia metallidurans CH34.*  
20 Dissertation, 2001, Martin-Luther-University Halle-Wittenberg). Black bar represent PhoA activity of *E. coli* cells expressing  $_{seq}$ PgQC-PhoA, striped bar displays PhoA activity of cells expressing  $\Delta$ BlaM-PhoA and served as positive control and cells expressed vector without insert were used as negative control (blank bar).

PhoA activity was determined from cultures grown as described above using chromogenic substrate p-nitrophenylphosphate (PNPP) (Pribyl, 2001). Therefore 200  $\mu$ l cell suspension with known OD600 was harvested at  
25 13000 rpm at 4°C for 10 min. Cell pellet was washed in 0.5 ml 10 mM Tris-HCl pH 8.0, 10 mM MgSO<sub>4</sub> und 1 mM iodoacetamide. Resulted cell pellet was resuspended in 1 ml 1 M Tris-HCl pH 8.0, 0.1 mM ZnCl<sub>2</sub> und 1 mM iodoacetamide. Then 50  $\mu$ l 0.1% (w/v) SDS and 50  $\mu$ l Chloroform was added to the mixture followed by an incubation time for 5 min at 37°C. The reaction was then initiated by addition of 100  $\mu$ l substrate solution (1 M Tris-HCl pH 8.0, 0.4% (w/v) PNPP). The reaction mixture was furthermore incubated at 37°C until the solution turns yellow. The  
30 reaction was then stopped by addition of 120  $\mu$ l 1 M KH<sub>2</sub>PO<sub>4</sub>, 0.5 M EDTA pH 8.0. The time taken to develop a yellow coloration defined specific enzymatic PhoA activity. Cell debris was removed by centrifugation (13000 rpm, 20 min) and optical density at 420 nm was determined of supernatant. PhoA activity was determined according to the Lambert-Beer law. *E. coli* CC118 pGP1-2 cultures bearing the empty vector pECD637 served as negative control

whereas *E. coli* CC118 pGP1-2 with pECD619 (Pribyl, 2001) served as positive control. This plasmid encodes a short form of  $\beta$ -lactamase (*blaM*) inclusive signal sequence downstream of *phoA* domain.


**Conclusion:** In silico analysis of open reading frame of PgQC revealed a putative signal sequence. This indicates a localization of PgQC outside the cytoplasm in *P. gingivalis*. C-terminal fusions of PgQC inclusive “native” signal sequences with alkaline phosphatase (PhoA) were constructed to investigate the “nature” localization of PgQC. Fusions with alkaline phosphatases are exclusively active when localized in the periplasm. Expression of  $seqPgQC$ -PhoA resulted in high phosphatase activity of 638.5 U/l  $\pm$  50.9 (Fig. 5). This indicates that PgQC is localized in the periplasm.

## VII. Description of synthetic methods

### a) Synthesis of 5-substituted imidazo[4,5-b]pyridineamines

5-substituted imidazo[4,5-b]pyridineamines were prepared by a general method comprising: treating 6-chloropyridine-2,3-diamine with triethyl orthoformate at elevated temperature to obtain 5-chloroimidazo[4,5-b]pyridine (Step A1); followed by a cross-coupling reaction of the product from Step A1 with a respective amine in the presence of a suitable Pd-catalyst and a base to obtain the corresponding 5-substituted imidazo[4,5-b]pyridineamine (Step A2).

The compound of Example 1 was prepared by the above method, as shown in the following Scheme 1.



**Scheme 1:** Synthetic scheme for the preparation of Example 1.

### Example 1: N-Benzylimidazo[4,5-b]pyridin-5-amine

Step A1: 5-Chloroimidazo[4,5-b]pyridine

A solution of 6-Chloropyridine-2,3-diamine (718 mg, 5 mmol) in Methanol (10 ml) and Triethyl orthoformate (10 ml) was heated to reflux for 3 hours. The volatiles were evaporated and the residue was purified by flash chromatography on silica using a  $CHCl_3$ -MeOH gradient. Yield: 540 mg (58%); ESI-MS  $m/z$  151.1  $[M+H]^+$

Step A2: N-Benzylimidazo[4,5-b]pyridin-5-amine


5-Chloro[4,5-b]pyridine (207 mg, 1.1 mmol, 1 eq), DavePhos (10 mg, 0.0264 mmol, 0.25 eq) and  $Pd_2(dba)_3$  (9 mg, 0.011 mmol, 0.1 eq) were dissolved in dry THF (15 ml) under Argon atmosphere.  $LiN(TMS)_2$  (1M in THF, 2.4 ml, 2.4 mmol, 2.2 eq) and benzylamine (144  $\mu$ l, 1.3 mmol, 1.2 eq) were added and the mixture was stirred at 65°C for 18 h. After cooling to room temperature the mixture was acidified by means of aqueous HCl (5 N) and stirring was continued for further 10 min. The reaction mixture was poured into saturated aqueous  $NaHCO_3$  and extracted with EtOAc (3x25 ml). The combined organic layers were dried over  $MgCO_3$  and evaporated to dryness. The residue was purified by semi-preparative HPLC. Yield: 90 mg (24%); MS  $m/z$ : 225.2  $[M+H]^+$ ; HPLC (Gradient A):  $rt$  8.93 min, 100

%;  $^1\text{H-NMR}$  (DMSO- $d_6$ )  $\delta$ : 4.55 (s, 2H); 6.80 (d, 1H,  $^3J=8.8$  Hz); 7.22-7.27 (m, 1H); 7.30-7.37 (m, 4H); 7.83-7.91 (m, 2H); 9.08 (s, 1H)

**b) Synthesis of 6-substituted imidazo[4,5-b]pyridineamines**

5 6-Substituted imidazo[4,5-b]pyridineamines were prepared by a general method comprising the steps: treating 2-chloro-3,5-dinitropyridine with ammonia in a suitable solvent or solvent mixture to obtain 3,5-dinitropyridin-2-amine (Step B1); treating the product obtained in Step B1 with  $(\text{NH}_4)_2\text{S}$  to obtain 5-nitropyridin-2,3-diamine (Step B2); treating the product obtained in Step B2 with triethyl orthoformate to obtain 6-nitroimidazo[4,5-b]pyridine (Step B3); treating the product obtained in Step B3 with a suitable reducing agent to obtain imidazo[4,5-b]pyridin-6-amine (Step B4); followed by treating the product obtained in Step B4 with a respective aldehyde in the presence of a suitable reducing agent, such as  $\text{NaBH}_4$ , to obtain the corresponding *N*-alkylimidazo[4,5-b]pyridin-6-amine (Step B5).

A synthetic route according to the above general method is exemplified in Scheme 2 below.



**Scheme 2:** Synthetic scheme for the preparation of 6-substituted imidazo[4,5-b]pyridineamines

15

**aa) Synthesis of Imidazo[4,5-b]pyridin-6-amine**

**Step B1: 3,5-Dinitropyridin-2-amine**

A solution of 2-Chloro-3,5-dinitropyridine (5 g, 24.6 mmol, 1 eq) in Ethanol (150 ml) was treated dropwise with aqueous  $\text{NH}_3$  (7 ml, 123 mmol, 5 eq) at  $0^\circ\text{C}$ . After complete addition, the mixture was stirred at ambient temperature for 1 hour. The solid product was collected by filtration and dried. The compound was used without further purification. Yield: 4.17 g (92%)

**Step B2: 5-Nitropyridin-2,3-diamine**

A solution of 3,5-Dinitropyridin-2-amine (3.9 g, 21.2 mmol, 1 eq) in Methanol (80 ml) was treated with 20% aqueous  $(\text{NH}_4)_2\text{S}$  (36.1 ml, 106 mmol, 5 eq) and heated to reflux for 1 hour. After cooling, the solid was collected by filtration and dried. The product was used without further purification. Yield: 3.2 g (98%); ESI-MS  $m/z$ : 155.0  $[\text{M}+\text{H}]^+$ ; HPLC (Gradient A): rt 4.08 min, 100 %;  $^1\text{H-NMR}$  (DMSO- $d_6$ )  $\delta$ : 5.31 (br s, 2H), 6.98 (br s, 2H), 7.36 (d, 1H,  $^4J=2.2$  Hz), 8.28 (d, 1H,  $^4J=2.6$  Hz)

25

**Step 3: 6-Nitroimidazo[4,5-b]pyridine**

A solution of 5-Nitropyridin-2,3-diamine (2.7 g, 17.5 mmol) in Methanol (14 ml) and Triethyl orthoformate (14 ml) was stirred at 150°C in a microwave for 10 min. The solvents were evaporated and the residue was used without further purification. Yield: 2.64 g (92%); ESI-MS m/z: 165.1 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 6.21 min, 100 %

**5 Step 4: Imidazo[4,5-b]pyridin-6-amine**

A solution of 6-Nitroimidazo[4,5-b]pyridine (1240 mg, 7.5 mmol, 1 eq) in aqueous hydrochloric acid (10 %) was treated with SnCl<sub>2</sub> (5076 mg, 22.5 mmol, 3 eq) and heated in a microwave to 100°C for 30 minutes. After cooling to room temperature the mixture was basified by means of aqueous NaOH (1 M) and evaporated. The residue was suspended in MeOH and filtered. The filtrate was evaporated and the residue was purified by flash chromatography (silica, CHCl<sub>3</sub>/MeOH gradient with 0.5% NH<sub>3</sub>). Yield: 993 mg (98%); ESI-MS m/z: 135.2 [M+H]<sup>+</sup>; HPLC (Gradient A):  
10 rt 1.47 min, 100 %

**bb) General procedure for the synthesis of N-Alyklimidazo[4,5-b]pyridin-6-amines****Step 5: N-Alyklimidazo[4,5-b]pyridin-6-amines**

15 Imidazo[4,5-b]pyridin-6-amine (1 eq) and the respective aldehyde (1 eq) were dissolved in EtOH (5 ml) and stirred at room temperature for 4 hours. NaBH<sub>4</sub> (1.5 eq) was added and stirring was continued over night. The reaction was quenched by means of water and extracted with EtOAc (3x20 ml). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was purified by flash chromatography (silica, CHCl<sub>3</sub>/MeOH gradient).

20 The following examples of 6-substituted imidazo[4,5-b]pyridineamines were prepared by using the above described methods.

**Example 2: N-Benzylimidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and  
25 Benzaldehyde (38 µl, 0.4 mmol) as described above. Yield: 30 mg (36%); MS m/z: 225.2 [M+H]<sup>+</sup>; HPLC (Gradient A):  
rt 8.45 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 4.33 (s, 2H); 6.35 (br s, 1H); 6.93 (s, 1H); 7.21-7.26 (m, 1H); 7.31-7.36 (m,  
2H); 7.39-7.43 (m, 2H); 7.94 (d, 1H, <sup>4</sup>J=2.6 Hz); 8.07 (s, 1H); 12.20 (br s, 1H).

**Example 3: N-(3,4,5-Trifluorobenzyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (67 mg, 0.5 mmol) and 3,4,5-  
30 Trifluorobenzaldehyde (80 mg, 0.5 mmol) as described above. Yield: 74 mg (53%); MS m/z: 279.1 [M+H]<sup>+</sup>; HPLC  
(Gradient A): rt 10.13 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 4.34 (d, 2H, <sup>3</sup>J=5.7 Hz); 6.44 (br s, 1H); 6.94 (s, 1H); 7.31-  
7.39 (m, 2H); 7.92 (d, 1H, <sup>4</sup>J=2.6 Hz); 8.10 (s, 1H); 12.16 (br s, 1H).

**Example 4: N-(4-Chlorobenzyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and 4-  
35 Chlorobenzaldehyde (52 mg, 0.4 mmol) as described above. Yield: 48 mg (50%); MS m/z: 259.1 [M+H]<sup>+</sup>; HPLC  
(Gradient A): rt 9.97 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 4.33 (s, 2H); 6.39 (br s, 1H); 6.91 (s, 1H); 7.36-7.45 (m, 4H);  
7.93 (d, 1H, <sup>4</sup>J=2.5 Hz); 8.08 (s, 1H); 12.22 (br s, 1H).

**Example 5: N-(3-Chlorobenzyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and 3-Chlorobenzaldehyde (42  $\mu$ l, 0.4 mmol) as described above. Yield: 70 mg (73%); MS m/z: 259.1 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 9.84 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 4.36 (d, 2H, <sup>3</sup>J=5.9 Hz); 6.42 (s, 1H); 6.93 (s, 1H); 7.27-7.31 (m, 1H); 7.35-7.39 (m, 2H); 7.45-7.47 (m, 1H); 7.93 (d, 1H, <sup>4</sup>J=2.3 Hz); 8.08 (s, 1H); 12.09 (br s, 1H).

**Example 6: N-(3-Methoxybenzyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and 3-Methoxybenzaldehyde (46  $\mu$ l, 0.4 mmol) as described above. Yield: 40 mg (42%); MS m/z: 255.1 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 8.51 min, 97%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 3.73 (s, 3H); 4.28-4.32 (m, 2H); 6.34 (br s, 1H); 6.80 (dd, 1H, <sup>3</sup>J=8.1 Hz, <sup>4</sup>J=1.9 Hz); 6.92 (s, 1H); 6.96-7.00 (m, 2H); 7.22-7.27 (m, 1H); 7.93 (d, 1H, <sup>4</sup>J=2.5 Hz); 8.07 (s, 1H); 12.18 (br s, 1H).

**Example 7: N-(4-Methoxybenzyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and 3-Methoxybenzaldehyde (46  $\mu$ l, 0.4 mmol) as described above. Yield: 25 mg (26%); MS m/z: 255.1 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 8.43 min, 97%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 3.72 (s, 3H); 4.24 (s, 2H); 6.25 (br s, 1H); 6.85-6.97 (m, 3H); 7.29-7.35 (m, 2H); 7.92 (d, 1H, <sup>4</sup>J=2.4 Hz); 8.06 (s, 1H); 12.13 (br s, 1H).

**Example 8: N-(3-Thienylmethyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and Thiophene-3-carbaldehyde (33  $\mu$ l, 0.4 mmol) as described above. Yield: 60 mg (70%); MS m/z: 231.2 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 7.63 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 4.31 (s, 2H); 7.03 (d, 1H, <sup>4</sup>J=2.5 Hz); 7.13 (dd, 1H, <sup>3</sup>J=4.9 Hz, <sup>4</sup>J=1.1 Hz); 7.37-7.40 (m, 1H); 7.49 (dd, 1H, <sup>3</sup>J=4.9 Hz, <sup>4</sup>J=3.0 Hz); 7.96 (d, 1H, <sup>4</sup>J=2.5 Hz).

**Example 9: N-(3-(1-Piperidyl)benzyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and 3-(1-Piperidyl)benzaldehyde (71 mg, 0.4 mmol) as described above. Yield: 56 mg (49%); MS m/z: 308.3 [M+H]<sup>+</sup>; HPLC (Gradient A): rt (double peak) 5.17/5.49 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 1.48-1.63 (m, 6H); 3.07-3.14 (m, 4H); 4.25 (s, 2H); 6.76-6.81 (m, 2H); 6.95 (d, <sup>4</sup>J=2.5 Hz); 6.99 (s, 1H); 7.14 (t, 1H, <sup>3</sup>J=7.8 Hz); 7.96 (d, 1H, <sup>4</sup>J=2.5 Hz); 8.15 (s, 1H).

**Example 10: N-(2-Pyridylmethyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and Pyridine-2-carbaldehyd (35  $\mu$ l, 0.4 mmol) as described above. Yield: 6 mg (7%); MS m/z: 226.2 [M+H]<sup>+</sup>; HPLC (Gradient B): rt 4.96 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 4.43 (s, 2H); 6.97 (d, 1H, <sup>4</sup>J=2.5 Hz); 7.25-7.30 (m, 1H); 7.42 (d, 1H, <sup>3</sup>J=7.8 Hz); 7.72-7.78 (m, 1H); 8.01 (d, 1H, <sup>4</sup>J=2.5 Hz); 8.27 (s, 1H); 8.55 (d, 1H, <sup>3</sup>J=4.5 Hz).

**Example 11: N-(3-Pyridylmethyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and Pyridine-3-carbaldehyd (35  $\mu$ l, 0.4 mmol) as described above. Yield: 15 mg (18%); MS m/z: 226.2 [M+H]<sup>+</sup>; HPLC

(Gradient B): rt 4.64 min, 94%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 4.38 (s, 2H); 7.01 (d, 1H, <sup>4</sup>J=2.5 Hz); 7.34-7.39 (m, 1H); 7.78-7.83 (m, 1H); 7.97 (d, 1H, <sup>4</sup>J=2.5 Hz); 8.21 (s, 1H); 8.46 (dd, 1H, <sup>3</sup>J=4.7 Hz, <sup>4</sup>J=1.4 Hz); 8.64 (d, 1H, <sup>4</sup>J=1.6 Hz).

**Example 12: N-(2,3-Dihydro-1,4-benzodioxin-6-yl-methyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and 1,4-  
5 Benzodioxane-6-carbaldehyd (61 mg, 0.4 mmol) as described above. Yield: 21 mg (20%); MS m/z: 283.2 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 8.59 min, 96%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 4.16-4.23 (m, 6H); 6.27 (br s, 1H); 6.77-6.94 (m, 4H); 7.91 (d, 1H, <sup>4</sup>J=2.5 Hz); 8.08 (s, 1H); 12.25 (br s, 1H).

**Example 13: N-(3,4-Dimethoxybenzyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (134 mg, 1 mmol) and 3,4-  
10 Dimethoxybenzaldehyde (166 mg, 1 mmol) as described above. Yield: 90 mg (32%); MS m/z: 285.2 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 7.79 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 3.70-3.76 (m, 6H); 4.24 (s, 2H); 6.24 (br s, 1H); 6.87-6.97 (m, 3H); 7.01-7.04 (m, 1H); 7.93 (d, 1H, <sup>4</sup>J=2.3 Hz); 8.07 (s, 1H); 12.16 (br s, 1H).

**Example 14: N-(3,4-Dichlorobenzyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and 3,4-  
15 Dichlorobenzaldehyde (65 mg, 0.4 mmol) as described above. Yield: 75 mg (69%); MS m/z: 293.1 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 11.09 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 4.36 (s, 2H); 6.45 (br s, 1H); 6.94 (d, 1H, <sup>4</sup>J=1.6 Hz); 7.39 (dd, 1H, <sup>3</sup>J=8.3 Hz, <sup>4</sup>J=1.7 Hz); 7.59 (d, 1H, <sup>3</sup>J=8.3 Hz); 7.66 (d, 1H, <sup>4</sup>J=1.6 Hz); 7.93 (d, 1H, <sup>4</sup>J=2.5 Hz); 8.09 (s, 1H); 12.25 (br s, 1H).

**Example 15: N-(4-Propoxybenzyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (134 mg, 1 mmol) and 4-  
20 Propoxybenzaldehyde (158 μl, 1 mmol) as described above. Yield: 110 mg (39%); MS m/z: 283.3 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 11.07 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 0.96 (t, 3H, <sup>3</sup>J=7.4 Hz); 1.70 (sext, 2H, <sup>3</sup>J=7.0 Hz); 3.88 (t, 2H, <sup>3</sup>J=6.5 Hz); 4.24 (s, 2H); 6.84-6.97 (m, 3H); 7.27-7.34 (m, 2H); 7.93 (d, 1H, <sup>4</sup>J=1.4 Hz); 8.07 (s, 1H); 12.18 (br s, 1H).

**Example 16: N-(4-(2-Aminoethoxy)benzyl)imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (268 mg, 2 mmol) and N-Boc-  
4-(2-Aminoethoxy)benzaldehyde (531 mg, 2 mmol) as described above, followed by Boc-deprotection using TFA/DCM (1:1, 2 ml) and TIS (100 μl) and purification by semi-preparative HPLC. Yield: 53 mg (9%); MS m/z: 284.1 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 5.12 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 3.18-3.25 (m, 2H); 4.13 (t, 2H, <sup>3</sup>J=5.0 Hz);  
30 4.31 (s, 2H); 6.94-6.99 (m, 2H); 7.07 (d, 1H, <sup>4</sup>J=2.4 Hz); 7.33-7.38 (m, 2H); 7.91-8.01 (m, 3H); 8.09 (d, 1H, <sup>4</sup>J=2.4 Hz); 8.85 (s, 1H).

**Example 17: 1-(2-(4-((Imidazo[4,5-b]pyridin-6-ylamino)methyl)-phenoxy)ethyl)guanidine**

A solution of N-(4-(2-Aminoethoxy)benzyl)imidazo[4,5-b]pyridin-6-amine\*TFA (41 mg, 0.08 mmol, 1 eq) in DMF was treated with N,N'-Bis(tert-butoxycarbonyl)-S-methylisothiourea (23 mg, 0.08 mmol, 1 eq), DMAP (1 mg,  
35 0.008 mmol, 0.1 eq) and TEA (33 μl, 0.24 mmol, 3 eq). The mixture was stirred for 16 hours at room temperature, quenched with water and extracted with EtOAc (3x20 ml). The combined organic layers were dried over MgCO<sub>3</sub> and

evaporated. Boc deprotection was carried out with TFA/DCM (1:1, 2 ml) and TIS (100  $\mu$ l). The volatiles were evaporated and the residue was purified by semi-preparative HPLC. Yield: 18 mg (41%); MS m/z: 326.1 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 5.95 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 4.04 (t, 2H, <sup>3</sup>J=5.3 Hz); 4.30 (s, 2H); 6.91-6.95 (m, 2H); 7.07 (d, 1H, <sup>4</sup>J=2.5 Hz); 7.32-7.36 (m, 2H); 7.64 (t, 1H, <sup>3</sup>J=5.8 Hz); 8.09 (d, 1H, <sup>4</sup>J=2.4 Hz); 8.86 (s, 1H).

5 **Example 18: N-[(4-Isopropoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (67 mg, 0.5 mmol) and 4-Isopropoxybenzaldehyde (78  $\mu$ l, 0.5 mmol) as described above. Yield: 6 mg (4%); MS m/z: 283.2 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 10.69 min, 89.7%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 1.23 (d, 6H, <sup>3</sup>J=5.9 Hz), 4.20-4.24 (m, 2H), 4.50-4.60 (m, 1H), 6.83-6.89 (m, 3H), 7.26-7.32 (m, 2H), 7.92 (br s, 1H), 8.05 (br s, 1H), 12.02 (br s, 1H)

10 **Example 19: N-[(3-Phenoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and 3-Phenoxybenzaldehyde (64  $\mu$ l, 0.4 mmol) as described above. Yield: 19 mg (16%); MS m/z: 317.3 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 12.13 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 4.30-4.36 (m, 2H), 6.41 (br s, 1H), 6.80-6.97 (m, 4H), 7.02-7.20 (m, 3H), 7.28-7.36 (m, 3H), 7.82-8.16 (m, 2H), 12.03 (br s, 1H)

15 **Example 20: N-[(4-Benzyloxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and 3-Benzyloxybenzaldehyde (79 mg, 0.4 mmol) as described above. Yield: 47 mg (38%); MS m/z: 331.2 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 12.59 min, 97.8%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 4.22-4.26 (m, 2H), 5.06 (s, 2H), 6.24 (br s, 1H), 6.86-7.00 (m, 3H), 7.28-7.45 (m, 7H), 7.90-7.93 (m, 1H), 8.05 (s, 1H), 12.05 (br s, 1H)

20 **Example 21: N-[(4-Biphenyl)methyl]-3H-imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (50 mg, 0.4 mmol) and 4-Biphenylcarboxaldehyd (68 mg, 0.4 mmol) as described above. Yield: 30 mg (27%); MS m/z: 301.2 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 12.37 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 4.37 (d, 2H, <sup>3</sup>J=5.4 Hz), 6.40 (br s, 1H), 6.94 (br s, 1H), 7.31-7.37 (m, 1H), 7.41-7.51 (m, 4H), 7.60-7.67 (m, 4H), 7.95 (s, 1H), 8.06 (s, 1H), 12.04 (br s, 1H)

25 **Example 22: N-[(2,6-Difluoro-4-methoxy-phenyl)methyl]-3H-imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (67 mg, 0.5 mmol) and 2,6-difluoro-4-methoxybenzaldehyde (86 mg, 0.4 mmol) as described above. Yield: 77 mg (53%); MS m/z: 291.2 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 9.60 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 3.76 (s, 3H), 4.22 (d, 2H, <sup>3</sup>J=5.9 Hz), 5.97 (br s, 1H), 6.71-6.79 (m, 2H), 7.10 (br s, 1H), 7.92 (s, 1H), 8.09 (s, 1H), 12.16 (br s, 1H)

30 **Example 23: N-[(7-Methoxy-1,3-benzodioxol-5-yl)methyl]-3H-imidazo-[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (60 mg, 0.45 mmol) and 5-Methoxypiperonal (81 mg, 0.45 mmol) as described above. Yield: 44 mg (33%); MS m/z: 299.2 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 8.91 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$ : 3.80 (s, 3H), 4.21 (s, 2H), 5.93 (s, 2H), 6.27 (br s, 1H), 6.63 (s, 1H), 6.72 (s, 1H), 6.94 (s, 1H), 7.91 (s, 1H), 8.07 (s, 1H), 12.23 (br s, 1H)



**Example 24: N-[(2,2-Difluoro-1,3-benzodioxol-5-yl)methyl]-3H-imidazo-[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (67 mg, 0.5 mmol) and 2,2-Difluoro-1,3-benzodioxole-5-carboxaldehyde (93 mg, 0.5 mmol) as described above. Yield: 60 mg (40%); MS m/z: 305.3 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 11.07 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 4.34 (d, 2H, <sup>3</sup>J=6.4 Hz), 6.45/6.26 (br s, 1H, Rotamer), 6.85/7.08 (br s, 1H, Rotamer), 7.22-7.31 (m, 1H), 7.33-7.38 (m, 1H), 7.43 (s, 1H), 7.85-8.15 (m, 2H), 12.02/12.59 (br s, 1H)

**Example 25: N-[[4-(2-Pyridyl)phenyl]methyl]-3H-imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (67 mg, 0.5 mmol) and 4-(2-Pyridyl)benzaldehyde (92 mg, 0.5 mmol) as described above. Yield: 25 mg (17%); MS m/z: 302.4 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 6.00 min, 100%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 4.39 (d, 2H, <sup>3</sup>J=5.9 Hz), 6.45 (br s, 1H), 7.29-7.35 (m, 1H), 7.51 (d, 2H, <sup>3</sup>J=8.3 Hz), 7.82-7.88 (m, 1H), 7.91-7.98 (m, 2H), 8.02-8.09 (m, 3H), 8.64 (d, 2H, <sup>3</sup>J=4.9 Hz), 12.02 (br s, 1H)

**Example 26: N-[[4-(2-Morpholinoethoxy)phenyl]methyl]-3H-imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (67 mg, 0.5 mmol) and 4-(2-Morpholinoethoxy)benzaldehyd (118 mg, 0.5 mmol) as described above. Yield: 21 mg (12%); MS m/z: 177.6 [M+2H]<sup>2+</sup>, 354.4 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 5.76 min, 100%; <sup>1</sup>H-NMR (MeOH-d<sub>4</sub>) δ: 2.55-2.61 (m, 4H), 2.78 (t, 2H, <sup>3</sup>J=5.4 Hz), 3.67-3.72 (m, 4H), 4.11 (t, 2H, <sup>3</sup>J=5.4 Hz), 4.30 (s, 2H), 6.87-6.93 (m, 2H), 7.02 (br s, 1H), 7.29-7.35 (m, 2H), 7.94 (s, 1H), 8.05 (s, 1H)


**Example 27: N-[[4-morpholinophenyl]methyl]-3H-imidazo[4,5-b]pyridin-6-amine**

The compound was synthesized starting from Imidazo[4,5-b]pyridin-6-amine (67 mg, 0.5 mmol) and 4-(4-Morpholinyl)benzaldehyde (96 mg, 0.5 mmol) as described above. Yield: 42 mg (26%); MS m/z: 310.4 [M+H]<sup>+</sup>; HPLC (Gradient A): rt 6.91 min, 93.9%; <sup>1</sup>H-NMR (MeOH-d<sub>4</sub>) δ: 3.07-3.11 (m, 4H), 3.79-3.82 (m, 4H), 4.29 (s, 2H), 6.91-6.96 (m, 2H), 7.01 (br s, 1H), 7.27-7.32 (m, 2H), 7.95 (br s, 1H), 8.04 (br s, 1H)

**cc) General procedure for the synthesis of N-Benzylimidazo[4,5-b]pyridin-6-amine-porphyrin conjugates****Step C1:**

Imidazo[4,5-b]pyridine-6-amine (1 eq) was dissolved in MeOH or EtOH (c = 0.05–0.08 M). The respective aldehyde was added and the mixture was stirred at room temperature until TLC indicated complete turnover of the starting materials. NaBH<sub>4</sub> (1.5 eq) (in the case of R<sup>a/b</sup> = <sup>1</sup>H) or NaBD<sub>4</sub> (1.7 eq) (in the case of R<sup>a/b</sup> = D), respectively, was added carefully and stirring was continued overnight. The volatiles were evaporated and the residue was purified by flash chromatography (Al<sub>2</sub>O<sub>3</sub>, CHCl<sub>3</sub>/MeOH gradient).

The purified product was dissolved in MeOH (c = 0.06–0.12 M) and treated with freshly prepared 1M HCl in MeOH (16 eq). After stirring at room temperature for 3 h, the volatiles were evaporated and the residue was used without further purification.



**Scheme 3:** Exemplary synthetic scheme for the synthesis of *N*-Benzylimidazo[4,5-*b*]pyridin-6-amine–porphyrin conjugates

- 5           **Step C2:**
- N-[[4-(2-Aminoethoxy)phenyl]-methyl]-1H-imidazo[4,5-*b*]pyridin-6-amine or N-[[4-(2-aminoethoxy)phenyl]dideo-terio-methyl]-1H-imidazo[4,5-*b*]pyridin-6-amine (1 eq) obtained by step C1 was dissolved in dimethylformamide ( $c=0.1\text{--}0.13$  M). Fmoc-Lys(Boc)-OH (1.2 eq), TBTU (1.2 eq) and DIPEA (4 eq) were added and the mixture was stirred at room temperature for 4-5 hours. Water was added and extracted with EtOAc (3x100 ml).
- 10 The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was purified by flash chromatography (Al<sub>2</sub>O<sub>3</sub>, CHCl<sub>3</sub>/MeOH gradient).


**Step C3:**

The respective product obtained by step C2 (1 eq) was dissolved in dimethylformamide ( $c = 0.03$  M), treated with DBU (1 eq) and stirred at room temperature for 30–40 minutes. A suitable porphyrin (1.2 eq), HOBT (1.2 eq),

TBTU (1 eq) and DIPEA (4 eq) were dissolved in dimethylformamide, premixed for 50 minutes at room temperature and added to the solution. The mixture was stirred at room temperature overnight. The reaction was carefully quenched by addition of TFA/DCM (1:1 v/v, 10 ml) and stirring was continued for 45 minutes. The volatiles were evaporated and the crude mixture was directly subjected to semi-preparative HPLC.

5


**Example 28: 3-[(1Z,4Z,9Z,15Z)-18-[3-[[[(1S)-5-Amino-1-[2-[4-[(3H-imidazo[4,5-b]pyridin-6-ylamino)methyl]phenoxy]-ethylcarbamoyl]pentyl]amino]-3-oxo-propyl]-3,8,13,17-tetramethyl-21,23-dihydroporphyrin-2-yl]-propanoic acid**



10 Yield (last step): 15 mg (6%); MS m/z: 453.1 [M+2H]<sup>2+</sup>; 904.8 (M+H)<sup>+</sup> HPLC (Gradient A): rt 12.43 min, 94%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 0.96-1.53 (m, 8H), 2.40-2.48 (m, 3H), 3.02-3.26 (m, 5H), 3.59-3.80 (m, 12H), 4.20-4.26 (m, 2H), 4.26-4.33 (m, 2H), 4.33-4.45 (m, 2H), 6.70 (d, 2H, J = 8.7 Hz), 7.04-7.08 (m, 1H), 7.17-7.24 (m, 2H), 7.42-7.51 (m, 3H), 7.87 (t, 1H, <sup>3</sup>J = 5.4Hz), 8.05-8.12 (m, 2H), 8.97 (br s, 1H), 9.34 (d, 1H, J = 24.0 Hz), 9.35 (s, 1H), 10.19 (d, 1H, J = 8.6 Hz), 10.32 (s, 1H), 10.33 (d, 2H, J = 9.8 Hz) 12.34 (br s, 1H).

15

**Example 29: 3-[(4Z,10Z,15Z,19Z)-18-[3-[[[(1S)-5-amino-1-[2-[4-[dideuterio-(1H-imidazo[4,5-b]pyridin-6-ylamino)-methyl]phenoxy]ethylcarbamoyl]pentyl]amino]-3-oxo-propyl]-3,8,13,17-tetramethyl-22,24-dihydroporphyrin-2-yl]propanoic acid**



20 Yield (last step): 37 mg (26%); MS m/z: 453.9 [M+2H]<sup>2+</sup>; 906.4 (M+H)<sup>+</sup> HPLC (Gradient A): rt 12.45 min, >99%; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ: 0.96-1.53 (m, 6H), 2.40-2.48 (m, 2H), 3.02-3.26 (m, 6H), 3.59-3.80 (m, 14H), 4.26-4.45 (m, 5H), 6.70 (d, 2H, J = 8.4Hz), 7.04-7.08 (m, 1H), 7.17-7.24 (m, 2H), 7.42-7.51 (m, 3H), 7.87 (m, 1H), 8.05-8.12 (m, 2H), 8.98 (br s, 1H), 9.34 (d, 1H, J = 23.7 Hz), 9.35 (s, 1H), 10.28 (d, 1H, J = 8.4 Hz), 10.31 (s, 1H), 10.33 (d, 2H, J = 10.0 Hz).

25

**c) Analytical methods**

**HPLC:** The analytical HPLC-system consisted of a Merck-Hitachi device (model LaChrom) utilizing a LUNA RP 18 (5 μm), analytical column (length: 125 mm, diameter: 4 mm), and a diode array detector (DAD) with λ = 214

nm as the reporting wavelength. The compounds were analyzed using a gradient at a flow rate of 1 mL/min; whereby eluent (A) was acetonitrile, eluent (B) was water, both containing 0.04 % (v/v) trifluoroacetic acid applying one of the following gradients:

5 Gradient A: 0 min – 5 % (A), 15 min – 60 % (A), 20 min – 95 % (A), 30 min – 95 % (A), 31 min – 5 % (A), 35 min – 5 % (A)

Gradient B: 0 min – 1 % (A), 5 min – 1 % (A), 20 min – 20 % (A), 30 min – 95 % (A), 34 min – 95 % (A), 35 min – 1 % (A), 37 min – 1 % (A)

The purities of all reported compounds were determined by the percentage of the peak area at 214 nm.

10 **Mass-spectrometry:** ESI- & APCI-Mass spectra were obtained with a SCIEX API 1200 spectrometer (Perkin Elmer) or an expression CMS (Advion).

**NMR-spectroscopy:** The <sup>1</sup>H NMR-Spectra were recorded at an Agilent DD2 400-MHz spectrometer. Chemical shifts are expressed as parts per million (ppm) downfield from tetramethylsilane. Splitting patterns have been designated as follows: s (singlet), d (doublet), dd (doublet of doublet), t (triplet), m (multiplet) and br (broad signal).

## INDUSTRIAL APPLICABILITY

The crystals and co-crystals according to the present invention are crystals of therapeutic target proteins (bacterial glutaminy cyclases, bacQCs) and can be specifically and substantially used for identifying inhibitors capable of selective targeting of periodontitis-inducing pathogens by using the methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors disclosed herein. Thus, the crystals are relevant to the treatment of a particular disease, e.g. periodontitis, and, accordingly, susceptible to industrial applicability.


The methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors according to the present invention are industrially applicable in view of the pharmaceutical relevance of the bacQC enzymes to the occurrence of periodontitis and their essentiality for the growth of periodontal pathogens demonstrated herein.

The compounds according to the present invention, including compounds identified by the methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors, and the pharmaceutical composition according to the present invention are also susceptible to industrial applicability, because these can be used in methods for treatment of the human or animal body, in particular in a method for therapy or prophylaxis of a bacterial infection, e.g. a bacterial infection caused by a bacterium selected from the group consisting of *Porphyromonas gingivalis*, *Prevotella intermedia* and *Tannerella forsythia*, and/or in a method for therapy or prophylaxis of an acute, chronic or recurrent periodontal disease, e.g. periodontitis.

35 The research activities leading to these results were supported by the European Union.

## CLAIMS

1. A compound according to the following Formula I,




I

its individual enantiomers, its individual diastereoisomers, its hydrates, its solvates, its crystal forms, its individual tautomers or a pharmaceutically acceptable salt thereof, wherein:

A is selected from the group consisting of optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted cycloalkyl and optionally substituted alkenyl;

R<sup>1</sup> is independently selected from the group consisting of H and optionally substituted alkyl;



R<sup>a</sup> and R<sup>b</sup> are the same or different from each other and are independently selected from the group consisting of H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroalkyl and optionally substituted heteroaryl, and wherein R<sup>a</sup> and R<sup>b</sup> can optionally be joined together to form a carbocyclic or a heterocyclic ring;

wherein "optionally substituted" refers to optional substitution by one or several groups independently selected from: C<sub>1-6</sub> alkyl, C<sub>1-6</sub> heteroalkyl, C<sub>1-6</sub> carbocyclyl, C<sub>1-5</sub> heterocyclyl and C<sub>1-5</sub> heteroaryl group, each of which may be substituted by one or several halogen atoms and/or hydroxyl groups; a halogen atom; a cyano group; a primary, secondary or tertiary amino group; a hydroxyl group; and a carboxyl group.

2. The compound according to claim 1, wherein:

said aryl is independently a C<sub>6-10</sub>, preferably C<sub>6</sub> aryl group;

said heterocyclyl is independently a monocyclic or bicyclic C<sub>1-11</sub>, preferably C<sub>2-8</sub>, more preferably C<sub>4-5</sub> heterocyclic group comprising 1 to 4 ring heteroatoms selected from N, S and O;

said alkyl is independently a linear or branched, open-chained or cyclic C<sub>1-6</sub>, preferably C<sub>1-4</sub>, more preferably C<sub>1-3</sub>, even more preferably C<sub>1-2</sub> alkyl group;


said cycloalkyl is independently a cyclic C<sub>3-6</sub>, preferably C<sub>4-6</sub>, more preferably C<sub>5-6</sub> alkyl group;

said alkenyl is independently a linear or branched, open-chained or cyclic C<sub>2-6</sub>, preferably C<sub>2-4</sub>, more preferably C<sub>2</sub> group comprising at least one C=C bond;

said heteroaryl is independently an aromatic monocyclic or bicyclic C<sub>1-11</sub>, preferably C<sub>2-8</sub>, more preferably C<sub>4-5</sub> heterocyclic group comprising 1 to 4 ring heteroatoms selected from N, S and O; and

said heteroalkyl is independently a linear or branched, open-chained or cyclic C<sub>1-5</sub>, preferably C<sub>1-3</sub>, more preferably C<sub>1-2</sub> heteroalkyl group comprising 1 to 4 heteroatoms selected from N, S and O.

3. The compound according to claim 1 to 2, which is represented by the following Formula Ia,




Ia

wherein A is selected from optionally substituted aryl and optionally substituted heteroaryl; and

R<sup>1</sup>, R<sup>a</sup> and R<sup>b</sup> are H.


4. The compound according to any one of claims 1 to 3, wherein R<sup>a</sup> and R<sup>b</sup> are independently selected from <sup>1</sup>H and D.
5. The compound according to any one of claims 1 to 4, wherein A is substituted by at least one substituent represented by the following structure B:

**B**

wherein  $n = 1, 2, 3, 4, 5$  or  $6$ ; and

$R^7$  and  $R^8$  are independently selected from alkyl, aryl, heteroalkyl, heteroaryl, carbamimidoyl, formyl, alkylacyl and arylacyl, each of which can optionally be further substituted and wherein  $R^7$  and  $R^8$  can be optionally joined together to form a carbocyclic or a heterocyclic ring.

6. The compound according to claim 5, wherein  $R^7$  is represented by the following structure E:


**E**

wherein  $M$  is selected from  $Fe^{2+}$  and  $Fe^{3+}$  or is absent;

$R^c$  and  $R^d$  are independently selected from  $-H$ ,  $-CH_3$ ,  $-CH=CH_2$ ,  $-SO_3H$  and  $-CH(OH)CH_2OH$ ; and

$X$  is selected from a covalent bond, an alkylene, aralkylene, heteroalkylene, carbocyclene, heterocyclene, heteroarylene, heteroaralkylene, aminoalkylene, alkylamino and carbonyl-alkylamino group; wherein each of these may have up to 12 carbon atoms and up to 11 heteroatoms in the main chain, and may be substituted by one or more  $C_{1-6}$  alkyl group(s),  $C_{1-6}$  heteroalkyl group(s),  $C_{1-6}$  carbocyclyl group(s),  $C_{1-5}$  heterocyclyl group(s),  $C_{1-5}$  heteroaryl group(s), halogen atom(s), hydroxyl group(s), cyano group(s), primary, secondary or tertiary amino group(s), carboxyl group(s) and side chain(s) derived from proteinogenic or non-proteinogenic aminoacid(s).

7. The compound according to claim 6, wherein  $X$  is represented by the following structure:




X

wherein  $m = 0, 1, 2$  or  $3$ , and

$R^e$  is a side chain derived from a proteinogenic amino acid.

8. The compound according to any one of claims 1 to 8, wherein A is substituted by a substituent represented by the following structure F:



F

wherein M is selected from  $Fe^{2+}$  and  $Fe^{3+}$  or is absent; and

$R^c$  and  $R^d$  are independently selected from  $-H$ ,  $-CH_3$ ,  $-CH=CH_2$ ,  $-SO_3H$  and  $-CH(OH)CH_2OH$ .

9. A compound according to any one of claims 1 to 8 for use in a method for treatment of the human or animal body.
10. A compound according to any one of claims 1 to 8 for use in a method for therapy and/or prophylaxis of a bacterial infection.
11. The compound according to any one of claims 1 to 8 for use in the method according to claim 9, wherein:



- (i) the bacterial infection is caused by a bacterium that expresses a bacterial glutaminy cyclase (bacQC), the bacQC being polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and an amino acid sequence having a sequence identity of 90% or more to any one of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; and/or
  - (ii) the bacterial infection is caused by a bacterium selected from the group consisting of *Porphyromonas gingivalis*, *Prevotella intermedia* and *Tannerella forsythia*; and/or
  - (iii) the compound selectively inhibits the growth of the bacterium within a biofilm.
12. A compound according to any one of claims 1 to 8 for use in a method for therapy or prophylaxis of an acute, chronic or recurrent periodontal disease.
13. The compound according to any one of claims 1 to 8 for use in the method according to claim 12, wherein the disease is selected from the group consisting of dental plaque-induced gingival diseases, chronic periodontitis, aggressive periodontitis, periodontitis as a manifestation of systemic diseases, necrotizing periodontal diseases, abscesses of the periodontium, periodontitis associated with endodontic lesions, peri-implant mucositis, peri-implantitis and endodontic infections.
14. The compound according to any one of claims 1 to 8 for use in the method according to any one of claims 9 to 13, wherein the route of administration is topical administration and/or wherein the method is a nonsurgical method.
15. A method for treatment of the human or animal body comprising administration of a therapeutically effective amount of a compound according to any one of claims 1 to 8 to a subject in need thereof.
16. A method for therapy and/or prophylaxis of a bacterial infection comprising administration of a therapeutically effective amount of a compound according to any one of claims 1 to 8 to a subject in need thereof.
17. The method according to claim 16, wherein:

- (i) the bacterial infection is caused by a bacterium that expresses a bacterial glutaminy cyclase (bacQC), the bacQC being polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and an amino acid sequence having a sequence identity of 90% or more to any one of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; and/or
  - (ii) the bacterial infection is caused by a bacterium selected from the group consisting of *Porphyromonas gingivalis*, *Prevotella intermedia* and *Tannerella forsythia*; and/or
  - (iii) the compound selectively inhibits the growth of the bacterium within a biofilm.
18. A method for therapy or prophylaxis of an acute, chronic or recurrent periodontal disease comprising administration of a therapeutically effective amount of a compound according to any one of claims 1 to 8 to a subject in need thereof.
19. The method according to claim 17, wherein the disease is selected from the group consisting of dental plaque-induced gingival diseases, chronic periodontitis, aggressive periodontitis, periodontitis as a manifestation of systemic diseases, necrotizing periodontal diseases, abscesses of the periodontium, periodontitis associated with endodontic lesions, peri-implant mucositis, peri-implantitis and endodontic infections.
20. The method according to any one of claims 15 to 18, wherein the route of administration is topical administration and/or wherein the method is a nonsurgical method.



## (C) SEQ ID NO. 1

10                    20                    30                    40                    50                    60  
 MKRLITGAA FLLAATLSAC NGNNTSETQG DRTEQAETVQ ADLFSADSAY TFVQRQVNFQ  
  
70                    80                    90                    100                    110                    120  
 PRIPGTAPHR ACGDWLVATL RSFGAAVQEQ TAEIKAHDGT MLPMRNIIAS YRPEATGRML  
  
130                    140                    150                    160                    170                    180  
 LMAHWDTRPV CDQDANPAMH TETFDGADDG GSGVGVLLLEI ARYLGQQKDL GMGIDIVFFD  
  
190                    200                    210                    220                    230                    240  
 TEDYGSYGDD ESWCLGSQYW SRNPHVAGYK AEAGILLDMV GAKGATFYWE YFSKSYAPGL  
  
250                    260                    270                    280                    290                    300  
 ISAVWQTAAA LGYGNYFIQA DGGALTDHVV PVIKNLGIPI IDIINYSSKN EHGFGDHWHT  
  
310                    320                    330  
 QRDNMQIIDK NVLDAVGETV IRYLDEQVKA ASH

## (D) SEQ ID NO. 2

10                    20                    30                    40                    50                    60  
 MDRMINKYAG VLLGSLILSC CGQKNTTKEE TTEPADTKR IEAPTFNADS AYAYIERQVA  
  
70                    80                    90                    100                    110                    120  
 FGPRVPNTEA HQRCADYLAG ELDRHGAKVY VQEAVLTAYN GEKLKAQNIV GAFQPEKSRF  
  
130                    140                    150                    160                    170                    180  
 VLLFAHWDSR PYADHDTDEA NHRKPIDGAD DGGSGVGILL EIARQIQAKA PAIGIDIVFF  
  
190                    200                    210                    220                    230                    240  
 DAEDYGTPEF VDEYKPDTCW LGSQFWAKNP HVPNYKAIEFG ILLDMVGSRG ATFYKESTSV  
  
250                    260                    270                    280                    290                    300  
 QYAARYVEKV WTAARELGYG KYFINAQGGA IVDDHQYVIQ GLRTPCLDII NYDPDTQSGF  
  
310                    320                    330  
 GPYWHTQNDT MENIDRETLK AVGETILNVI YNH

FIG. 1




FIG. 2




FIG. 3(A)




FIG. 3(B)




FIG. 3 (C)






FIG. 4




FIG. 5







FIG. 6



(C) hQC



(B) TfQC



(A) PgQC

FIG. 7






FIG. 8






FIG. 9






FIG. 10

INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2019/054476

A. CLASSIFICATION OF SUBJECT MATTER  
 INV. C07D471/04 C07D401/12 C07D401/10 C07D407/10 C07D409/12  
 C07D413/12 A61K31/519 A61P31/04  
 ADD.  
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
 Minimum documentation searched (classification system followed by classification symbols)  
 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	European Commission: "Final Report Summary - TRIGGER (King of hearts, joints and lungs; periodontal pathogens as etiologic factor in RA, CVD and COPD and their impact on treatment strategies.)", 16 August 2017 (2017-08-16), XP002781083, Retrieved from the Internet: URL:https://cordis.europa.eu/result/rcn/202357_en.html [retrieved on 2018-05-15] the whole document	1-20
A	WO 02/068409 A1 (MERCK & CO INC [US]; CLAIBORNE CHRISTOPHER F [US]; BUTCHER JOHN W [US]) 6 September 2002 (2002-09-06) example 104 ----- -/--	1-20

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search <b>29 March 2019</b>	Date of mailing of the international search report <b>10/04/2019</b>
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer <b>Schmid, Arnold</b>
--	---

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2019/054476

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2016/171755 A1 (FORMA THERAPEUTICS INC [US]) 27 October 2016 (2016-10-27) page 18, line 1 -----	1-20
A	WO 2008/028617 A1 (HOFFMANN LA ROCHE [CH]; HONOLD KONRAD [DE]; SCHAEFER WOLFGANG [DE]; SC) 13 March 2008 (2008-03-13) abstract; examples 6.1-6.4 -----	1-20
A	US 4 977 144 A (FUJIMOTO ROGER A [US] ET AL) 11 December 1990 (1990-12-11) column 9, line 16; examples 4,14 -----	1-20



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2019/054476

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 02068409	A1	06-09-2002	
		AT 324371 T	15-05-2006
		AU 2002252053 B2	14-09-2006
		BG 108113 A	30-04-2005
		BR 0207526 A	09-03-2004
		CA 2438895 A1	06-09-2002
		CN 1503793 A	09-06-2004
		CZ 20032258 A3	14-01-2004
		DE 60210944 T2	19-04-2007
		DK 1379520 T3	21-08-2006
		EA 200300919 A1	26-02-2004
		EC SP034744 A	28-10-2003
		EE 200300403 A	15-12-2003
		EP 1379520 A1	14-01-2004
		ES 2261658 T3	16-11-2006
		GE P20063741 B	10-02-2006
		HR P20030669 A2	30-06-2005
		HU 0303258 A2	28-01-2004
		IL 157254 A	26-11-2008
		IS 6902 A	31-07-2003
		JP 4179879 B2	12-11-2008
		JP 2004524314 A	12-08-2004
		KR 20030076703 A	26-09-2003
		MX PA03007621 A	04-12-2003
		NO 20033732 A	22-10-2003
		NZ 527365 A	26-08-2005
		PL 364625 A1	13-12-2004
		PT 1379520 E	31-08-2006
		SI 1379520 T1	31-08-2006
		SK 10542003 A3	02-03-2004
		UA 75392 C2	15-12-2003
		US 2002165241 A1	07-11-2002
		US 2004209889 A1	21-10-2004
		WO 02068409 A1	06-09-2002
		YU 64303 A	25-05-2006
		ZA 200306159 B	05-07-2004
-----			
WO 2016171755	A1	27-10-2016	
		US 2016311774 A1	27-10-2016
		US 2018141910 A1	24-05-2018
		WO 2016171755 A1	27-10-2016
-----			
WO 2008028617	A1	13-03-2008	
		AU 2007294149 A1	13-03-2008
		BR PI0716477 A2	18-03-2014
		CA 2662031 A1	13-03-2008
		CN 101511828 A	19-08-2009
		EP 2064213 A1	03-06-2009
		JP 2010502660 A	28-01-2010
		KR 20090038487 A	20-04-2009
		US 2009318428 A1	24-12-2009
		WO 2008028617 A1	13-03-2008
-----			
US 4977144	A	11-12-1990	NONE
-----			